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Thursday 11th October 2012
Session 1 Interventional Cardiology
Chairs: Prof. David Foley & Dr. Colm Hanratty
18.30–21.00 Case Reviews
Session 2 Electrophysiology
Chairs: Prof. David Keane & Dr. Joe Galvin
18.30–21.00 Case Reviews/Presentations
Friday 12th October 2012
08.45 Registration
08.45–09.00 Welcome from Dr Carol Wilson, President
Session 3 Imaging
Chair: Dr. Nicola Johnston
09.00–09.30 Assessment of Aortic Valve Stenosis
Dr Simon Ray
Wythenshawe Hospital, Manchester, UK
09.30–10.30 Oral Presentations
1. The Yield of Stress Perfusion CMR in Diabetic Patients
O´ h-Icı´ D, Moynagh A, Hovasse T, Unterseeh T, Louvard Y, Morice MC, Garot J,
Institut Cardiovasculaire Paris Sud, Hoˆpital Jacques Cartier, 6 avenue du Noyer Lambert, 91 300 MASSY, France
2. Diagnosis of Left Ventricular Non Compaction by Cardiovascular Magnetic Resonance Imaging in a Group of Patients with Left
Ventricular Systolic Dysfunction
Noad, RL, McKeag NA, Johnston, N, Horan, P, Harbinson M, Dixon LJ
Belfast Heart Centre, Belfast
3. Giant Cell Myocarditis in the CMR Era
Leong T
Harefield Hospital, Royal Brompton & Harefield NHS Foundation Trust, London, UK
4. A Method of Studying the Course of Myocardial Ischemia and Reperfusion in Rats in Vivo
1O h-Ici D, 2Dietrich T, 1Kuehne T, 1Messroghli D
1Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Augustenburger Platz,
Berlin 13353, Germany
2German Heart Center Berlin, Department of Cardiology, Berlin, Germany
 The Author(s) 2012. This article is published with open access at Springerlink.com
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the source are credited.
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5. Cigarette Smoking: Relationship with Inflammation, Arterial Stiffness, and Subclinical Atherosclerosis. The Multi-Ethnic Study
of Atherosclerosis (MESA)
McEvoy JW, Blaha MJ, Lima JAC, Bluemke DA, Hundley WG, Min JK, Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff MJ,
Blumenthal RS, Nasir K
John Hopkins Hospital, Baltimore, MD, USA
6. Cardiac CT for the Assessment of Pain and Plaque: The 90 day Results of a Randomised Control Trial
McKavanagh P, Lusk L, Ball P, Trinick T, Duly, Walls G, Harbinson M,
McQuillan CL, Shevlin S, Alkali M, Donnelly P
Ulster Hospital, Dundonald, Belfast
10.30–11.00 Poster Presentation
Coffee/Exhibition
7. Angiotensin-Converting Enzyme Inhibition and Non-Dipping Hypertensives—Targeting Night-Time Blood Pressure to Improve
Ventricular Function
Voon V, Ledwidge M, O’Hanlon R, McDonald K
St. Vincent’s University Hospital, Elm Park, Dublin
8. Wavelet Analysis of Blood Flow Velocity Waveforms Detects Differences in the Retro-Bulbar Circulation Between Heart
Failure Patients and Controls
1Lyons K S, 2McCann A, 1McVeigh G E, 1Harbinson M T,
1Centre for Vision and Vascular Science, Queens University Belfast
2 Medical Physics Agency, Belfast Health and Social Care Trust
9. High Sensitivity Troponin T is Detectable in Most Patients with Clinically Stable Heart Failure
1Lyons KS, 2McKeeman G, 1McVeigh G, 1Harbinson MT
1Centre for Vision and Vascular Science,
2QUB, Belfast Link Labs, Belfast HSC Trust
10. Potentially Inappropriate Medicines in Heart Failure
Bermingham M, McDonald K, Ledwidge M
Heart Failure Unit, St. Vincent’s University Hospital, Dublin and School of Medicine and Medical Science,
University College Dublin, Dublin
11. Surgical Repair of Ischaemic Ventricular Septal Defects within 9 days of a Myocardial Infarct did not Lead to any Survivors in a
13 year Series of 26 Patients
Beattie G, Martel G, MacGowan S, Graham A
Royal Victoria Hospital Belfast, Belfast
12. Coronary Computed Tomography in Acute Chest Pain in the Emergency Department: Appropriate Patient Selection Informed by
Multicenter Randomized Control Trials
Groarke J
Brigham and Women’s Hospital, Boston, Ma, USA
13. Variation in Measures of Right Ventricular Structure and Function Performed in Standard versus Modified Apical Views
Groarke J, Rivero J, Cheng S
Brigham and Women’s Hospital/Harvard Medical School, Boston, Ma, USA
14. Cardiovascular MRI Findings in an Asymptomatic Male HIV Patient Population
Morgan RB, Loy A, O’ Dea S, Takacs A, Mulcahy F, Meaney J, Daly CA
St. James’s Hospital, Dublin
15. Reduced Right Ventricular Myocardial Strain in the Elite Athlete is not a Consequence of Myocardial Damage
1King GJ, 2Murphy R, 2Almuntaser I, 1Mc Loughlin B, 1Livingston A, 1 Nevin S, 1Clarke JC
1Eagle Lodge Medical Centre O’ Connell Avenue Limerick
2St James Hospital Cardiology Department, Dublin
16. The Use of a Novel Iterative Reconstruction Algorithm CT to Assess Stable Chest Pain with: Results from the CAPIR study
McKavanagh P, Lusk L, Ball P, Trinick T, Duly E, Walls G, Harbinson M, McQuillan CL, Shevlin S, Alkali M, Donnelly P
Department of Cardiology, Ulster Hospital, Dundonald, Belfast
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17. Impact of Coronary Computed Tomographic Angiography Results on Patient and Physician Behavior in a Low-Risk Population
McEvoy JW, Blaha MJ, Nasir K, Yoon YE, Choi EK, Cho IS, Chun EJ, Choi SI, Rivera JJ, Blumenthal RS, Chang HJ
John Hopkins Hospital, Baltimore, MD, USA
Session 4 Heart Failure/Prevention
Chair: Dr. Pat Nash
11.00–11.30 ‘‘ABPM is Now Mandatory for Good Clinical Practice’’
Prof. Eoin O’Brien
Prof. of Molecular Pharmacology
Conway Institute, University College Dublin
11.30–12.30 Oral Presentations
18. Community Management of Cardiovascular Risk in Stage A/B Heart Failure: Six Month Follow up of the COMPARE-HF Cohort
Horgan S, Tallon E, Dawkins I, Conlon C, Watson C, Baugh J, Whyte K, Miwa S, McDonald K, Ledwidge M
St Vincent’s University Hospital, Dublin
19. The Hidden Truth: Stage B Heart Failure Among Diabetics and Overweight
Murtagh G, O’ Connell J, Dawkins I, King T, Griffin J, Tallon E, O’ Hanlon R, Patel A, Ledwidge M, Mc Donald KM
St Vincent’s University Hospital
20. Reduced Absolute Myocardial Blood Flow is Associated with Worse Diastolic Dysfunction
Groarke JD, Murthy VL, Naya M, Di Carli MF, Shah AM
Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, Boston, USA
21. Diabetic Hearts Show Increased Iysyl Oxidase Expression
Horgan S, Watson C, Collier P, Ledwidge M, McDonald K, Baugh J
The Conway Institute, University College Dublin, Dublin
22. Identification of Serum Biomarkers that Reflect Progressive Cardiac Remodelling
Watson C, Collier P, Horgan S, Conlon C, O’Hanlon R, Ledwidge M, Baugh J, McDonald K
UCD Conway Institute of Biomolecular and Biomedical Research, Belfield, University College Dublin, Dublin
23. Assessing Psychological Well-Being in a Population Undergoing Screening for Inheritable Cardiac Diseases
McQuade C, McShane C, McGorrian C, O’Donnell C, O’Neill J, Keelan E, Galvin J, Mahon NG, Codd M
Family Heart Screening Clinic, Mater Misericordiae University Hospital, Dublin
12.30–14.00 Lunch/Exhibition
Session 5 Structural Heart Disease
Chair: Dr. Andrew Maree
14.00–14.30 Invited Speaker
Prof. Alain Carpentier
Hopital Europeen Georges Pompidou, Paris, France
14.30–15.30 Oral Presentations
24. Long Term Prevention of Recurrent Cerebrovascular Events with Transcatheter Patent Foramen Ovale Closure- Findings in
Contrast to the Closure I trial
Margey R, Elmariah S, Renfigo-Moreno P, Inglessis I, Palacios IF
Structural Heart Disease, Interventional Cardiology and Structural Heart Disease, Division of Cardiology, Massachusetts General
Hospital, Boston, USA
25. Thrombus on Left Atrial Appendage Occluder Device: Periprocedural Caution
Waterhouse DF, Mehta AG, Abidin NZ, Kennedy MW, Alqaseer M, Asegom SD, Foley D, McAdam B
Beaumont Hospital, Beaumont, Dublin
26. Catecholamine-Induced Heart Hypertrophy: Impact on Cardiac Function
1Lainis F, 2Buckley MM, 2Johns EJ
1School of Medicine & 2Department of Physiology, University College Cork, Cork
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27. Cost Benefit Analysis of Transcatheter Aortic Valve Implantation (TAVI) Compared to Conventional Medical Treatment
Including Valvuloplasties in Patients with Severe Aortic Stenosis (AS)
1Neoh S, 2Mahon C, 3Kiat C, 1Galvin B, 2Sugrue R, 3O’Neill C, 1Crowley J, 2Foley B, 2Crean P, 1Sharif F
1 University College Hospital Galway
2 St. James’s Hospital, Dublin
3 AMNCH, Dublin
28. Conventional Aortic Valve Replacement Surgery in Patients not Suitable for Trans- Catheter Aortic Valve- Outcome
Assessment
Beattie R, Booth K, Spence M, Jones MJ
Royal Victoria Hospital, Belfast
29. Current Demand for Surgery for Rheumatic Heart Disease in Northern Ireland
Umar Imran Hamid, Alastair Graham
Royal Victoria Hospital, Belfast
15.30–16.00 Poster Presentations
Coffee/Exhibition
30. Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolus: Beating the Odds
Galvin M, James S, Waterhouse DF, Abidin NZ, Asgedom SD, McAdam B, Foley D,
Department of Interventional Cardiology and Department of Interventional Echocardiography, Beaumont Hospital, Dublin
31. Incidence of Cardiomyopathy in Heamochromatosis; are We Cautious Enough?
Asaad Khan, G. Kaur, Z. Khan, N. Papaneja,
C. Quigley
Wexford General Hospital, Wexford
32. Non-Cerebrovascular Systemic Arterial Embolic Events due to Paradoxical Embolization via Patent Foramen Ovale (PFO)
1?2 Margey R, 1Elmariah S, 1Hynes BG, 1Renfigo-Moreno P, 2Schainfeld R, 2Jaff M R, 1Inglessis I, 1Palacios IF
1Interventional Cardiology and Structural Heart Disease, Division of Cardiology, Massachusetts
2Vascular Medicine, Division of Cardiology, Massachusetts General Hospital and Harvard Medical School,
Boston, Mass
33. Trans-Catheter Aortic Valve Implantation: Adverse Outcomes of 120 Cases in 2 Centres
1Sugrue R, 1Teehan S, 1+2Murphy RT, 1Lynch G, 2McCarthy J, 1Tolan M, 2Quinn M, 1Foley B, 1+2Crean P
1Departments of Cardiology and Cardiothoracics, St James’ University Hospital, Trinity College, Dublin
2Blackrock Clinic, Dublin
34. Radiation Exposure during Transcatheter Aortic Valve Implantation (TAVI) Procedures
Sharma D, Ramsewak A, O’Conaire S, Spence M, Manoharan G
Royal Victoria Hospital, Belfast
35. Hypertension Patterns Post Aortic Coarctation Repair
Canniffe C, Walsh K
Mater Misericordiae Hospital, Dublin
36. Perceived Barriers to Exercise in a Cardiovascular Primary Prevention Programme
Tuohy S, Sharma K, O’Conghaile A, Windle J, Gibson I, Flaherty G, Crowley J
University College Hospital, Galway
37. Cigarette Smoking: Association between Inflammation, Subclinical Atherosclerosis and Cardiovascular Events
McEvoy JW, Blaha MJ, Lima JAC, Bluemke DA, Hundley WG, Min JK, Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff M J,
Blumenthal RS, Nasir K
Johns Hopkins Hospital, Baltimore, USA
38. Impact of a Phase 2 Cardiac Rehabilitation Programme on Exercise Performance Across Patient Subgroups:
Who Benefits Most?
Neylon A, McGorrian C, Gallagher A, Murphy A, Blake G, Mahon N, McCann H, Sugrue D
Department of Cardiology, Mater Misericordiae University Hospital, Dublin
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Session 6 Young Investigator Award
Chair: Dr Carol Wilson
Judges: Dr. Simon G. Ray, Dr. Peter Kearney & Dr. Angie Brown
16.00–17.00 Oral Presentation
39. Patients with Hypertension and Heart Failure with Preserved Ejection Fraction Present with Elevated Inflammatory and
Alternative Monocyte/Macrophage-Specific Markers in their Peripheral Circulation
Glezeva N, Voon V, Watson C, Ledwidge M, McDonald K, Baugh J
Conway Institute, UCD, Dublin
40. A Novel Biomarker and Potential Treatment for Diastolic Dysfunction and Heart Failure
Horgan S, Watson C, Collier P, Ledwidge M, McDonald K, Baugh J
The Conway Institute, UCD, Dublin
41. Carotid Intima-Media Thickness Independently Predicts Significant Coronary Artery Disease and is as Good as a Bank of Novel
Risk Markers
Leong T
Adelaide & Meath Hospital, Tallaght, and St. James’s Hospital, Dublin
42. Cardiovascular Magnetic Resonance of Myocardial Edema Using a Short Inversion Time Inversion Recovery (STIR) Black-
Blood Technique: Diagnostic Accuracy of Visual and Semi-Quantitative Assessment
1O h-Ici D, 2Ridgway JP, 1Kuehne T, 1Berger F, 3Plein S, 4Sivananthan M, 1Messroghli DR
1Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Augustenburger Platz 1,
Berlin 13353, Germany
2 Medical Physics, Leeds General Infirmary, Great George Street, Leeds UK
3 Leeds Institute, UK
17.00–17.30 ICS AGM
17.45–18.45 Stokes Lecture





Saturday 13th October 2012
08.00–09.15 Cardiology Education and Training Update
09.00–9.30 Cardiovascular Research in Ireland; evolution & role of the National Cardiovascular & Stroke Research Network (NCSRN)
Prof. Dermot Kenny
Cardiovascular Biology, Clinical Research Centre, Royal College of Surgeons in Ireland, Dublin
09.30–09.40 Brian McGovern Travelling Fellowship 2010 Report
Dr. Ronan Margey
Session 7 Revascularisation
Chair: Dr. John Riddell
09.40–10.00 ‘‘Get if off your chest’’
Three presentations on Topical Subjects
10.00–11.00 Oral Presentations
43. Impact of Stent Overlap on Long-Term Clinical Outcome in Patients undergoing Newer-Generation Drug-Eluting Stent
Implantation
O’Sullivan CJ, Stefanini GG, Pilgrim T, Ra¨ber L, Taniwaki M, Bu¨llesfeld L, Khattab AA, Nietlispach F, Wenaweser P, Meier B,
Windecker S
Swiss Cardiovascular Centre, Bern University Hospital, Bern, Switzerland
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44. Contemporary Predictors in Successful PCI of Chronic Total Occlusions
Leong T
Institut Cardiovasculaire Paris Sud, Paris, France
45. Long-term Clinical Outcomes of Percutaneous Coronary Intervention with Drug-Eluting Stents in Patients with Mechanical
Heart Valves
O’Sullivan CJ, Moschovitis A, Zanchin T, Stortecky S, Stefanini GG., Pilgrim T, Ra¨ber L, Taniwaki M, Bu¨llesfeld L, Khattab
AA, Nietlispach F, Wenaweser P, Meier B, Windecker S
Swiss Cardiovascular Centre, Bern University Hospital, Bern, Switzerland
46. Radial Artery Occlusion
M Dooley, M Spence, M Roberts
Belfast Health and Social Care Trust, Belfast
47. Optical Coherence Tomography (OCT) Guided Assessment of Coronary Intervention
Hillery P, Waterhouse DF, Abidin NZKZ, Asgedom SD, McAdam B, Foley DP
Beaumont Hospital, Beaumont, Dublin
48. The Changing Profile of Patients Undergoing Urgent Coronary Artery Bypass Surgery in the Primary Percutaneous Intervention
Era
R Beattie, C Wilson, ANJ Graham
Royal Victoria Hospital, Belfast
11.00–11.30 Poster Presentations
Coffee/Exhibition
49. Myocardial Tissue Hypoxia is Associated with Changes in the Epigenome
Watson C, Neary R, Collier P, Tolan M, Ledwidge M, McDonald K, Baugh J
UCD Conway Institute of Biomolecular and Biomedical Research, Belfield, University College Dublin
50. Refining Transcatheter Left Atrial Appendage Closure: Eliminating the Anaesthestist and Reducing the Cost
Waterhouse DF, Kennedy MW, Asgedom SD, Neylon A, Alqaseer M, McAdam B, Foley DP
Department of Cardiology, Beaumont Hospital, Dublin
51. Incidence and Outcome of Re-entry Injury in Redo Cardiac Surgery
Hamid UI, Chi San Leung S, McGrath Soo L, Graham A
Royal Victoria Hospital Belfast, Belfast
52. Radial Approach To CTO Re-canalisation is as Successful and Safer Than Femoral : Single Centre Observational Study
Asgedom SD, Bjornsstad PM, Patten R, McAdam B, Sheahan R, Foley DP
Beaumont Hospital, Beaumont, Dublin
53. An Audit of Acute Kidney Injury (AKI) Following Contrast Coronary Angiography
Connolly M, Mc Eneaney D, Harbinson M, Morgan N
Cardiovascular Research, Craigavon Cardiac Centre, Southern Trust, NI
54. Long-Term Survival of Patients Successfully Discharged Following Aborted Out of Hospital Cardiac Arrest
Keaney J, Cuddy S, Browne L, Hanley A, O’Sullivan J, Mahon N, Keelan E, McGorrian C, Galvin J
Mater Hospital Dublin
55. Utility of Highly-Sensitive Cardiac Troponin I as a Marker of Disease in Hypertrophic Cardiomyopathy
1,2McGorrian C, 3Lyster S, 4Tarrant H, 2Codd M, 5Doran P, 4Fitzgibbon M, 1,6Galvin J, 1Mahon NG
1Department of Cardiology, Mater Misericordiae University Hospital; 2UCD School of Public Health, Physiotherapy and
Population Science, UCD; 3UCD School of Biomolecular and Biomedical Sciences, UCD; 4Department of Clinical
Biochemistry, Mater Misericordiae University Hospital; 5UCD Clinical Research Centre, Mater Misericordiae University
Hospital; 6Department of Cardiology, Connolly Hospital Blanchardstown
56. Implications of Following New NICE Guidance on Pts Presenting to the Rapid Assess Chest Pain Clinic
Shevlin S, Johnston N, Dougon J
Royal Victoria Hospital, Belfast
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57. Pericardial Effusion Associated with Neoadjuvant Chemoradiation for Oesophageal Cancer at a Tertiary Referral Centre—An
Eight-Year Experience
Sugrue R, Fitzgerald C, Molony P, O’Hare D, McCormack O, Ravi N, Murphy R, Daly C, Reynolds JV
Departments of Upper Gastrointestinal Surgery and Cardiology
St James University Hospital, Trinity College, Dublin
Session 8 Electrophysiology/General Cardiology
Chair: Dr. Donal Murray
11.30–12.00 Invited Speaker
Prof. Michael Joy, OBE
Professor in Clinical Cardiology, University of Surrey
12.00–13.00 Oral Presentations
58. A Comparative Cost Impact Study of Diamond Forrester and Coronary Calcium
McKavanagh P, Lusk L, Ball P, Trinick T, Duly E, Walls G, Harbinson M, McQuillan CL, Shevlin S, Alkali M, Donnelly P
Department of Cardiology, Ulster Hospital, Dundonald, Belfast
59. Routine Trans-Oesophageal Echocardiography Directed Cardioversion in Patients with Atrial Fibrillation Treated with
Dabigatran—A Single Centre Experience
Kennedy MW, Waterhouse DF, Sheahan R, Gumbrielle T, Foley DF, McAdam BF
Dept of Cardiology, Beaumont Hospital, Dublin
60. A Pilot Study on Renal Sympathetic Denervation for Resistant Hypertension in the West of Ireland
Kalyar I, Gleeson J, Lappin D, Crowley J, Nash P, MacNeill B, Daly K, Sharif F
Cardiology Department, Galway University Hospitals, Galway
61. ABC for Life: A Programme of BLS Training to Primary School Children in Northern Ireland Since 2004
P Mc Grath, L Laverty, P Toner, M Connolly
‘ABC for life’ charity committee, Queen’s University Belfast, NI
62. Initial Experience with Vernakalant for Rapid Conversion of New Onset Atrial Fibrillation
Abidin NZ, Waterhouse DF, Foley D, Sheahan RS, McAdam B
Dept of Cardiology, Beaumont Hospital, Dublin
63. The Current Use of Oral Anticoagulation in Atrial Fibrillation Patients
Morgan RB, Mahon C, Sugrue R, Lynch M, Blennerhassett L, Curtin E, McMahon G, Murphy RT, Mulvihill N, Foley B,
Crean P, Daly CA
St. James’s Hospital, Dublin
13.00 Close of Meeting
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Session 3: Imaging
1 The Yield of Stress Perfusion CMR in Diabetic
Patients
O´ h-Icı´ D, Moynagh A, Hovasse T, Unterseeh T, Louvard Y,
Morice MC, Garot J
Institut Cardiovasculaire Paris Sud, Hoˆpital Jacques Cartier,
6 avenue du Noyer Lambert, 91 300 Massy, France
Background: The benefit of screening asymptomatic diabetic
patients for CAD remains unclear. Recent ADA consensus statement
concluded that routine screening is not recommended, whereas
ACCF/AHA guidelines suggest that stress myocardial perfusion
imaging may be considered for advanced cardiovascular risk assess-
ment. We wished to assess the yield of stress perfusion cardiac MRI
(CMR) in a diabetic population.
Methods: All patients who underwent stress CMR at our institute
(n = 4589) between November 2009 and September 2010 were
identified through the use of the cardiology database. Exclusion cri-
teria included history of documented myocardial infarction, prior
percutaneous coronary intervention, and prior coronary artery bypass
grafting. For patients who underwent multiple tests during this time
period, only the first test was included. The study population con-
sisted of 2,737 patients.
Results: Similar percentages of diabetic and nondiabetics had
abnormal scans (34.8 vs. 30.8 %, p = 0.05). Diabetics were more
likely to have inducible ischemia (14.4 vs. 11.2 %, p = 0.02), but
both groups were equally likely to have evidence of infarction on
delayed enhancement images (23.7 vs. 22.2 %).
Asymptomatic and symptomatic diabetic patients had similar per-
centages of ischemia (13.5 vs. 15.8 %, p = 0.40), and infarction (21.9
vs. 24.9 %, p = 0.36).
Symptomatic diabetic patients had more ischemia (15.8 vs.
11.1 %, p = 0.03), but similar rates of infarction (21.9 vs. 21.2 %,
p = 0.79) than symptomatic nondiabetic patients.
Conclusion: Stress testing in asymptomatic diabetics identifies a high
percentage of patients with ischemia and unknown myocardial
infarction. Diabetic patients have higher rates of ischemia than non-
diabetic patients. Whether knowledge of silent infarction should
change management is as yet unknown.
2 Diagnosis of Left Ventricular Non Compaction
by Cardiovascular Magnetic Resonance Imaging in
a Group of Patients with Left Ventricular Systolic
Dysfunction
Noad RL, McKeag NA, Johnston N, Horan P, Harbinson M,
Dixon LJ
Belfast Heart Centre, Northern Ireland
Introduction: Left ventricular non compaction (LVNC) cardiomy-
opathy is characterised by excessive trabeculations which
communicate with the left ventricular cavity. Novel imaging modal-
ities such as cardiovascular magnetic resonance (CMR) have
increased the frequency of diagnosis of this uncommon cardiomy-
opathy. Degrees of LVNC have been noted in normal subjects, and in
association with other cardiomyopathies. A ratio of end diastolic (ED)
Trabeculated and ED Compacted left ventricular myocardium (TC) of
greater than 2.3 is currently an echocardiographic diagnostic criterion
for LVNC cardiomyopathy.
Aim: The aim of this study was to measure the degree of LVNC in a
group of patients with left ventricular systolic dysfunction (LVSD).
Methods: We measured the EDTC ratio in 150 patients with an
ejection fraction of less than 50 % undergoing CMR imaging in our
centre over a 1 year period. Measurements were taken from the
standardised 16 segment model. The TC ratio was calculated for each
segment.
Results: The cause of LVSD was ischaemic heart disease (IHD) in
49.3 % of patients, dilated cardiomyopathy (DCM) in 13.3 % of
patients, various causes in 37.4 %. No patient had a previously
established diagnosis of LVNC cardiomyopathy. Mean LVEF was
34.1 %. Mean age was 62.2 years and 74 % were male. 39 % of
patients had a TC ratio greater than 2.3 in at least one segment.
Furthermore, 14 % had a TC ratio greater than 2.3 in more than one
segment. The most commonly affected segments were apical anterior
and apical lateral. Patients with DCM were the most likely to have
one or more affected segments (45 %), with IHD the second most
common aetiology (39 %) (p = 0.063).
Conclusion: A significant proportion of patients with impaired LVSD
had evidence of LVNC in more than one segment when analysed
utilising current echocardiographic diagnostic criteria. Further studies
are urgently required to clarify and reappraise diagnostic features of
this previously uncommon condition using CMR imaging to deter-
mine if LVNC has been overdiagnosed by CMR or previously
underdiagnosed as a cause of LVSD.
3 Giant Cell Myocarditis in the CMR Era
Leong T
Harefield Hospital, Royal Brompton & Harefield NHS Foundation
Trust, London
Background: Giant cell myocarditis (GCM) is rare with paucity of
data. We sought to review cases of histologically-proven GCM to
examine in particular, the potential role of cardiac magnetic reso-
nance (CMR) imaging in the diagnosis and treatment.
Results: Of 16 patients with histologically-proven GCM who pre-
sented to our institution, a national transplant centre, five had CMR
performed with two having repeat CMR. Of these, 4 were in car-
diogenic shock at the time of biopsy (patients 1, 2, 4, 5). Their times
from presentation at our institution to time of endomyocardial biopsy
(and initiation of treatment) were 0, 3, 11, 0 and 8 days, respectively,
while their times from presentation to first CMR were 12, 31, 9, 56
and 545 days, respectively. Table 1 summarises their CMR findings
of moderate to severe reduction in left ventricular (LV) systolic
function largely due to increase in end-systolic volumes (ESV) and
their patterns of late gadolinium enhancement (LGE). All patients
received steroids as well as immunosuppression: azathioprine/cyclo-
sporin (Patient 3), and rATG (Patients 1, 2, 4, 5). Patient 4 had
worsening of her LV from echo surveillance, leading to re-biopsy and
follow-up CMR. Her re-biopsy did not show active GCM, and her
follow-up CMR did not show any change in LGE, raising the pos-
sibility of deterioration in LV EF from adverse remodeling, and
therefore, did not have repeat immuno-suppressive therapy. Figure 1
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shows (a) widespread mid-wall LV LGE, (b) lateral wall fibrosis on
the explant (H&E 920) (c) GCM on biopsy (H&E 9200) of Patient 4
who had CMR and who subsequently underwent cardiac
transplantation.
Conclusions: In this largest known CMR series of histologically-
proven GCM, LGE on CMR imaging tends to be widespread
involving all layers of the myocardium as opposed to the typical
patterns of ‘classical’ myocarditis. This was representative of exten-
sive inflammation and fibrosis which may reflect the high mortality
associated with GCM.
Table 1 Summary of CMR findings
CMR quantification (median, IQR)
LV EDV (ml) 158 (133, 175)
LV ESV (ml) 98 (75, 108)
LV EF (%) 39 (39, 53)
RV EDV (ml) 140 (123, 145)
RV ESV (ml) 63 (61, 75)
RV EF (%) 53 (49, 58)
LGE patterns Patient 1—Mid-wall LGE: septum and
inferior wall. No oedema
Patient 2—Transmural LGE: inferior wall at
papillary muscle level with oedema
Patient 3—Widespread sub-endocardial and
mid-wall LGE. RV involvement
Patient 4—Subendocardial LGE: basal and
inferior septum, mid and apical inferior,
inferolateral and part of apical anterior wall.
Mid-wall and epicardial LGE: mid-anterior
septum and anterior walls. RV involvement




LV EDV change ?5 ml
LV ESV change ?15 ml
LV EF change -22 %
RV EDV change ?13 ml
RV ESV change ?24 ml
RV EF change -10 %
Patient 4
LV EDV change ?43 ml
LV ESV change ?56 ml
LV EF change -35 %
RV EDV change ?53 ml
RV ESV change ?19 ml
RV EF change ?2 %
Fig. 1 GCM Correlation. a CMR: mid-wall late gadolinium enhance-
ment in the LV, b Explant morphology: lateral wall fibrosis (H&E,
x20) and c Histology: endomyocardial biopsy (H&E, x200)
4 A Method of Studying the Course of Myocardial
Ischemia and Reperfusion in Rats In Vivo
1O´ h-Icı´ D, 2Thore D, 1Titus K, 1Messroghli D
1Department of Congenital Heart Disease and Pediatric Cardiology,
Deutsches Herzzentrum Berlin, Augustenburger Platz, Berlin 13353,
Germany; 2Department of Cardiology, German Heart Center Berlin,
Berlin, Germany
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Background: The use of MRI for the study of ischemia and its
consequences in small animals has been limited by the need for a
thoracotomy and operative occlusion of the coronary arteries. The
trauma of the surgery may be an important confounder in this open-
chest model. The closure of the coronaries with a suture does not
allow multiple occlusion-reperfusion cycles, and has limited the study
of ischemia–reperfusion in small animals.
Objective: To develop a ‘‘closed chest’’ model of ischemia–reper-
fusion, which would allow ischemia and infarction to be studied in
real-time while the rat is in the MRI environment.
Materials and methods: We developed a method of implanting a
balloon occluder to the left coronary artery. Male Sprague–Dawley
rats (n = 12, weight 367 ± 67 g) were anaesthetized and then intu-
bated. The heart was exposed by an incision in the fourth rib space.
The occluder was then secured loosely to the myocardium with a 6-0
non-absorbable suture. Occlusion and reperfusion of the coronary
artery was confirmed by visual inspection (blanching of the left
ventricle) and by ECG (ST-segment elevation and normalization) on
brief inflation and deflation of the balloon. The tubing of the occluder
was then tunneled to the intra scapular area. The tubing was then
looped in a subcutaneous pocket and the incision at the back was
closed. The animals were then allowed to recover from the operation
for at least 5 days. For coronary occlusion and MRI scanning, rats
were again anaesthetized, the tubing was exposed by reopening the
incision on the back, it was then connected to a syringe, and animals
were placed in the MRI scanner.
Results: There was a very low mortality rate for the implantation of
the coronary occluder (8.3 %). Inflation of the occluder on the MRI
table resulted in myocardial ischemia in all animals as documented by
ECG, and allowed the effects of ischemia and reperfusion on myo-
cardial edema and function to be studied serially before, during, and
after coronary occlusion. The changes in ECG were visible on the
standard Philips console. There was no visible artifact from the
occluder on any of the images.
Conclusions: The use of a pre-implanted balloon occluder allows for
studying of the effects of single or repeated myocardial ischemia and
reperfusion with MRI in real-time in a closed-chest rat model. As the
current treatment of myocardial infarction is urgent revascularization,
this model is more clinically relevant than a simple infarction model.
A more physiologically suitable model should aid the study of the
complex mechanisms involved.
5 Cigarette Smoking: Relationship with Inflammation,
Arterial Stiffness, and Subclinical Atherosclerosis. The
Multi-Ethnic Study of Atherosclerosis (MESA)
McEvoy JW, Blaha MJ, Lima JAC, Bluemke DA, Hundley WG,
Min JK, Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff MJ,
Blumenthal RS, Nasir K
John Hopkins Hospital, Baltimore, MD, USA
Background: Smoking is a major reversible cardiovascular risk
factor. Large population studies, incorporating measures of inflam-
mation and subclinical atherosclerosis, may provide a means to study
the effects of smoking further.
Methods: MESA is a population-based study of 6815 adults, free of
baseline cardiovascular disease, recruited from 6 US sites. We strat-
ified participants based on smoking status into 3 groups: never (NS),
former (FS), and current (CS). FS and CS were further stratified into
quartiles of pack-year history of tobacco exposure (PYH). We
assessed cross-sectional associations of smoking with markers of
inflammation [C-reactive protein (CRP), fibrinogen, and interleukin
L-6 (IL-6)], arterial stiffness (aortic distensibility by magnetic reso-
nance imaging), and subclinical atherosclerosis (SCA) [carotid
intima-media thickness (cIMT), and coronary artery calcification
(CAC)] by robust linear regression as well as prevalence ratio
regression using a generalized linear model and binomial error dis-
tribution, after adjustment for covariates. We excluded 23 participants
without information on smoking status from the final analysis.
Results: CS comprised 887 (13 %, mean age 58 years), FS 2487
(37 %, 63 years) and NS 3418 (50 %, 62 years) participants. CS were
more likely to be younger, male, Caucasian or African American, and
have lower LDL-C. The 3 inflammatory markers studied were all
elevated in CS. Compared to NS, the adjusted odds ratios for prev-
alence of CRP C2 were 1.2 (p \ 0.001) for former and 1.9
(p \ 0.001) for CS, respectively. Amongst FS and CS, increased
inflammation was noted in the highest quartile of PYH. Aortic dis-
tensibility was reduced in CS only, and no association was seen with
PYH. However, cIMT and CAC were elevated in both FS and CS,
with a greater burden of disease in the highest quartile of PYH.
Conclusion: These findings suggest a dose–response association
between smoking and markers of inflammation as well as measures of
SCA. Only current smoking was associated with reduced aortic
distensibility.
6 Cardiac CT for the Assessment of Pain and Plaque:
the 90 day Results of a Randomised Control Trial
McKavanagh P, Lusk L, Ball P, Trinick T, Duly, Walls G,
Harbinson M, McQuillan CL, Shevlin S, Alkali M, Donnelly P
Ulster Hospital, Dundonald, Belfast
Objective: To determine the accuracy and cost impact of the diamond
forrester (DF) and calcium score (CS) pathways proposed by NICE
clinical guideline 95 (CG95).
Method: This was a sub-study of the cardiac CT for the assessment of
chest pain and plaque (CAPP) study, a larger randomised control trial
(ISRCTN52480460), evaluating the cost-effectiveness of cardiac CT
in stable patients. The CAPP study recruited 500 participants referred
to NHS Rapid Access Chest Pain Clinics with suspected coronary
artery disease. This work involved the 250 patients randomised to the
CT arm of the CAPP study. The total number and cost for initial and
further investigations was determined theoretically by two models.
Model A used the DF criteria and Model B the CS criteria.
Results: Of the 250 patients, 4 withdrew. 140 (57 %) patients were
male. The mean DF was 47.8 and mean CS 172.5. Of the 52 patients
that had a DF score of 0–9 % 1 (1.9 %) had severe disease and of the
91 that had a DF[60 % 17 (18.7 %) had no CAD. Of the 126 patients
that had a CS of zero 2 (1.6 %) patients had severe disease and of the
26 patients with a CS [400 only 4 (15.4 %) did not have severe
disease. A Kendall’s tau-c (sc), rank correlation coefficient was
performed with CS showing a better correlation (sc 0.768, SE 0.026)
with CAD compared to the DF (sc 0.44, SE 0.047). In the costing
analysis CS proved to be less expensive in all scenarios considered.
Conclusions: The use of CS to triage all patients appears to be more
economical and accurate for the prediction of CAD and prevents
unnecessary downstream testing.
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7 Angiotensin-Converting Enzyme Inhibition and Non-
Dipping Hypertensives—Targeting Night-Time Blood
Pressure to Improve Ventricular Function
Voon V, Ledwidge M, O’Hanlon R, McDonald K
St. Vincent’s University Hospital, Elm Park, Dublin
Purpose: Blood pressure (BP) optimization remains a central focus in
strategies to prevent heart failure (HF). The non-dipper (ND), defined
by failure of nocturnal BP to fall by 10 %, is an emerging risk factor
profile for ventricular dysfunction in patients with hypertension. ND
has been shown to persist independent of conventional anti-hyper-
tensive strategies targeting daytime figures. As effective strategies
modulating this risk profile are yet to be proven, we aim to investigate
the impact of night-time administered angiotensin-converting enzyme
inhibition on clinical, biochemical and Doppler-echocardiographic
parameters on ND.
Methods: This prospective study randomized 45 ND with asymp-
tomatic hypertension and optimally treated daytime BP to additional
night-time administered perindopril (2.5–5 mg/night) (intervention)
or conventional daytime anti-hypertensives (controls) over 3 months.
Patients were assessed with B-type natriuretic peptide (BNP), 24-h
ambulatory BP monitoring and Doppler-echocardiography at baseline
and follow-up.
Results: Baseline demographics for all patients were assessed
[65.2 ± 9.4 years, male 58 %, diabetes 47 %, body mass index
[30 kg/m2, average daytime systolic BP (SBP) 127 ± 8, diastolic BP
(DBP) 72 ± 7 mmHg, follow-up duration 3.3 ± 0.8 months, BNP
47.5 ± 59.6 pg/mL, creatinine 72 ± 20 mmol/L, LVEF 68 ± 7 %].
At baseline, there were no significant differences in cardiovascular
phenotype between both groups. At follow-up, the intervention group
showed higher transmitral flow velocities versus controls (1.0 ± 0.3
vs. 0.8 ± 0.2, p \ 0.05). The intervention group also showed signif-
icant within-group reductions of nighttime BP and 24-h SBP (all
p \ 0.05). BNP levels and ND profiles persisted in both groups.
Conclusion: This study demonstrates that additional nocturnal
administered perindopril reduces BP over a 24-h period and improves
diastolic function (E/A) in ND with treated hypertension. Despite that,
the persistence of ND profile and elevated BNP suggest an underlying
active fibro-inflammatory pathology not resolved by current short-
term therapeutic strategy. More work is needed to understand the
pathophysiology of ND in the effort to prevent heart failure.
8 Wavelet Analysis of Blood Flow Velocity Waveforms
Detects Differences in the Retro-Bulbar Circulation
Between Heart Failure Patients and Controls
1Lyons KS, 2McCann A, 1McVeigh GE, 1Harbinson MT
1Centre for Vision and Vascular Science, Queens University Belfast;
2Medical Physics Agency, Belfast Health and Social Care Trust
Introduction: Heart failure (HF) is a clinical syndrome in which
neurohormonal activation and cardiac remodelling occur in response
to a pathological event. Microvascular dysfunction has been demon-
strated in the setting of HF, however, the effect of HF on the retro-
bulbar circulation is unknown. Our department has developed a novel
method for analysing blood flow velocity waveforms obtained from
vascular sites of interest which has been shown to detect differences
in waveform morphology between healthy controls and patients with
a variety of conditions associated with endothelial dysfunction.
Methods: As part of a study assessing biochemical and functional
measures of endothelial function in HF, blood flow velocity wave-
forms from the ophthalmic and central retinal arteries were obtained
from 32 patients with HF (mean age 64 years, 78 % male, 50 %
ischaemic) and 10 age and sex-matched controls. HF patients were on
maximum tolerated medical therapy with no hospital admissions for
exacerbations in the previous 6 months. Waveforms were analysed
using a discrete wavelet transform which decomposes each signal into
constituent sinusoidal waveforms. Traditional measures used in
waveform analysis [resistive index (RI) and pulsatility index (PI)]
were determined, as well as mean amplitude of 9 contributory fre-
quency bands determined by wavelet analysis. RI, PI and mean
amplitude for each frequency band were compared using non-para-
metric statistics.
Results: Mean amplitude of frequency bands 5 and 8 were signifi-
cantly higher in patients compared to controls for both ophthalmic
(p = 0.048 and p = 0.002) and central retinal artery (p = 0.028 and
p = 0.028) waveforms. In contrast, RI and PI were not different
between groups.
Conclusion: Wavelet analysis of blood flow velocity waveforms
provides a novel method for detecting microvascular dysfunction in
HF and is more sensitive than traditional measures of waveform
analysis such as RI and PI. Abnormalities of microvascular function
in HF are widespread.
9 High Sensitivity Troponin T is Detectable in Most
Patients with Clinically Stable Heart Failure
1Lyons KS, 2McKeeman G, 1McVeigh G, 1Harbinson MT
1Centre for Vision and Vascular Science; 2QUB, Belfast Link Labs,
Belfast HSC Trust
Introduction: Troponin levels are used in the diagnosis of acute
coronary syndromes (ACS), however, levels may be elevated in many
other conditions which may coexist in patients at risk of ACS. A
significant proportion of patients with stable heart failure (HF) have
detectable levels of troponin using standard third and fourth genera-
tion assays, however, the incidence of detectable levels of high
sensitivity troponin T (hs TnT) in HF patients is not well studied [1].
Methods: As part of a trial assessing vascular function in patients
with systolic HF, 32 subjects had hsTnT levels measured at baseline.
Patients had clinically stable HF, on maximal tolerated therapy with
no recent admissions for exacerbations. HsTnT was measured on a
multichannel analyser (Roche E Module).
Results: At baseline 27 (84.4 %) patients had detectable levels of
hsTnT [median 13.8 ng/L (9.2–21.4)]. 14 (43.8 %) patients had levels
above the 99th percentile of the normal range. When comparison was
made between patients with ischaemic and non-ischaemic HF, 12
(75 %) patients in the non-ischaemic group and 15 (94 %) in the
ischaemic group had detectable levels of hsTnT [median 13.93 ng/L
(11.8–20.2) versus 13.71 ng/L (4.6–26.3); p = 0.80].
Conclusions: The majority of patients with stable HF will have
detectable levels of hsTnT using new high sensitivity assays, and a
significant proportion of these will be above the cut-off point used for
diagnosis of ACS. If these patients present to hospital, modest ele-
vations in hsTnT do not necessarily indicate recent ACS, and serial
measurements should not be undertaken if not clinically indicated.
References
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10 Potentially Inappropriate Medicines in Heart
Failure
Bermingham M, McDonald K, Ledwidge M
Heart Failure Unit, St. Vincent’s University Hospital, Dublin and
School of Medicine and Medical Science, University College Dublin,
Dublin
Introduction: Heart failure (HF) patients frequently have multiple
co-morbidities requiring pharmacotherapy. However, a number of
frequently prescribed medicines are contraindicated or cautioned for
use in HF. This study sought to establish the extent of prescribing of
potentially inappropriate medicines (PIM) in HF and the costs asso-
ciated with PIMs in a stable, outpatient HF population.
Methods: A guideline and literature review was performed and 19
PIMs were identified. The Delphi consensus method was used to assess
these medicines. Specialists scored each medicine on a Likert scale to
establish the likelihood of it causing harm in a HF patient. The medi-
cation record of patients attending for annual review at the St Vincent’s
University Hospital Heart Failure Unit was reviewed by a pharmacist
with reference to the PIM list. Total number of PIM and total cost price
(Euro) was calculated. All analyses were carried out in SPSS v18.
Results: Medication records of 350 consecutive patients were
reviewed of whom 228 (65.1 %) were male. The mean age of the
population was 72.7 ± 11.6 years. A total of 380 PIM were identified
in 264 patients (75.4 %). This accounted for 15.1 % of all medicines
prescribed. The most frequently occurring PIM was low dose aspirin
(n = 197, 56.3 %), followed by inhaled beta2-agonists (n = 62,
17.7 %) and dihydropyridine calcium channel antagonists in HF
patients with ischaemic heart disease (IHD) (n = 25, 7.1 %). Patients
prescribed C1 PIM were more likely to have IHD, chronic obstructive
pulmonary disease and diabetes and less likely to have atrial fibril-
lation than those with no PIM. Total cost of prescribed PIMs was
€3907.45 per month.
Conclusion: HF patients remain at risk of being prescribed a PIM
despite being cared for in a HF disease management programme.
More data is required to clarify potential benefits associated with
pharmacist HF medicines review.
11 Surgical Repair of Ischaemic Ventricular Septal
Defects Within 9 Days of a Myocardial Infarct did not
Lead to Any Survivors in a 13 Year Series of 26 Patients
Beattie G, Martel G, MacGowan S, Graham A
Royal Victoria Hospital Belfast, Belfast
Objective: Ischaemic ventricular septal defects (VSDS) occur in
1–2 % of all myocardial infarctions and account for 5 % of deaths
following a myocardial infarction. The incidence is declining but it
still presents a significant challenge to the cardiology and cardiac
surgical team when they occur. Debate still remains in the literature
which is driven by large North American centres about when is the
correct time to operate on these patients. The objective was to assess
if the outcomes in our unit was dependent on the timing of the
operation compared to the original time of infarction.
Methods: 49 patients were identified with an ischaemic VSD. 26
patients had surgery and of the 26 patients 21 had a medical record
available which permitted an accurate identification of the time of
myocardial infarct. The surgical details were compiled from the
national cardiac surgery database.
Results: The mean age of patients was 69. 57 % had an inferior VSD.
Mean pre operative CVP was 12.9, PA diastolic 18.7. 58 % of cases were
repaired using the Toronto exclusion technique. 66 % had simultaneous
grafts. Post operatively 58 % of patients had a residual VSD. In hospital
mortality was 48 %, however, 5 year survival excluding in hospital
deaths was 50 %. No patient operated on within 9 days of a myocardial
infarction survived and no patient with a Euroscore above 80 was dis-
charged from hospital. The overall survival at 5 years was 30 %. Patients
with a residual VSD post operatively did poorly and was the only factor to
reach significance as a predictor of mortality.
Conclusions: This series of data would indicate that although a very
small sample size there is no evidence that early surgery in our unit is
associated with improved survival. The overall survival at 30 % is in
keeping with the UK average.
12 Coronary Computed Tomography in Acute Chest
Pain in the Emergency Department: Appropriate
Patient Selection Informed by Multicenter Randomized
Control Trials
Groarke J
Brigham and Women’s Hospital, Boston, MA, USA
Background: Coronary computed tomographic angiography (CCTA)
is considered an appropriate tool for investigating patients presenting
with chest pain (CP), normal/equivocal ECG and cardiac biomarkers,
no known coronary artery disease (CAD) who have a low to inter-
mediate pre-test probability of CAD. Such patients account for up to
70 % of all CP presentations to Emergency Departments (EDs). In
this context, CCTA has been shown to have excellent sensitivity and
negative predictive value. The likelihood of cardiovascular events in
the early years following a CT demonstrating normal or non-
obstructive (\50 %) stenosis is very low. A review of the multicenter
trials examining the role of CCTA in the ED is necessary to guide
appropriate patient selection for CCTA and to direct national ED
CCTA service planning and provision.
Methods: A complete review of all multicenter randomized controlled
trials (RCTs) where CCTA was compared with standard of care (SOC)
or nuclear myocardial perfusion imaging (MPI) was performed.
Results: Three relevant multicenter RCTs have been reported, all
since September 2011: CT-STAT, ACRIN-PA and ROMICAT II
trials. All trials included low to intermediate risk ED patients pre-
senting with CP. CT-STAT trial compared CCTA versus nuclear
MPI, whereas the other trials compared CCTA versus SOC. In total,
1,770 patients were randomized to the CCTA arm and 1,299 patients
to control arms of these trials. All trials demonstrated that a CT based
strategy for evaluating such patients safely reduced time to diagnosis
and reduced length of hospital stay. Two trials demonstrated a sig-
nificant increase in direct discharges from ED among CCTA cohorts,
without an increase in missed acute coronary syndrome (ACS). The
two trials that analyzed total ED costs demonstrated reduced costs
associated with CCTA strategy. All trails analyzed downstream
invasive coronary angiography (ICA); only one of three trials dem-
onstrated a significant increase downstream ICA (12 % post-CCTA
and 8 % post-SOC; p = 0.04).
Conclusions: Clinical trial evidence is accumulating to support use of
CCTA in evaluating select patients presenting with acute CP to EDs.
A review of the multicenter trials to date suggest that patients pre-
senting with CP to ED, who satisfy the following criteria, may be
appropriately evaluated with CCTA: age 40–74 years, normal/
equivocal ECG and initial cardiac biomarkers, low to intermediate
pre-test probability of CAD, no known CAD, no significant renal
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dysfunction, where clinical suspicion of ACS is high enough to
warrant further testing.
13 Variation in Measures of Right Ventricular
Structure and Function Performed in Standard
Versus Modified Apical Views
Groarke J, Rivero J, Cheng S
Brigham and Women’s Hospital/Harvard Medical School, Boston,
MA, USA
Background: Variation in morphology and function of the right
ventricle (RV) has been associated with adverse outcomes in
asymptomatic as well as symptomatic individuals. Thus, the ability to
accurately measure such variation is critically important. Guidelines
now recommend that echocardiographic assessments of the RV
should include measurements performed in an apical view that
maximizes the diameter of the chamber. However, the extent to which
RV measurements made in this modified view differ from those made
in a standard apical view is uncertain.
Methods: In a random sample of 43 patients (mean age 57 ± 17
years, 53 % women) who underwent clinical echocardiography, we
compared measurements of RV structure and function performed in
the standard apical 4-chamber view versus the modified ‘‘RV-focused
view.’’
Results: Of the patients studied, 9 % had an LVEF\50 and 51 % had
a PASP [40 mmHg. Measures of RV structure were larger in the
modified than in the standard views for short-axis dimensions
(4.1 ± 0.6 vs. 3.7 ± 0.7 cm for RVD1, and 3.2 ± 0.5 vs.
2.8 ± 0.6 cm for RVD2; P \ 0.003 for both), but similar for long-
axis dimension (6.8 ± 0.9 vs. 7.0 ± 0.9 cm for RVD3; P = 0.50).
All dimensions were only moderately correlated between the modi-
fied and standard views (r = 0.43–0.50; P \ 0.01). With respect to
measures of RV function in modified versus standard views, TAPSE
was higher, S’ was similar, and FAC was lower.
However, functional measures were all strongly correlated between
views, and these correlations remained strong irrespective of age, sex,
BMI, LVEF, and PASP. In addition, patients identified as having
abnormal RV function were largely similar with respect to mea-
surements made in the modified compared to standard views.
Conclusion: When performed in a modified RV-focused view,
compared to the standard apical 4-chamber view, measures of RV
structure are only moderately correlated; on the other hand, measures
of RV function are strongly correlated, particularly S’. Therefore, in
the absence of readily available RV-focused images, measurements of
RV function performed in the standard apical four-chamber view are
likely to still be quite informative.
14 Cardiovascular MRI Findings in An Asymptomatic
Male HIV Patient Population
Morgan RB, Loy A, O’Dea S, Takacs A, Mulcahy F, Meaney J,
Daly CA
St. James’s Hospital, Dublin
Aims: To study an asymptomatic group of HIV positive men on
antiretroviral therapy (ART) and compare them to age and sex mat-
ched controls in order to detect underlying cardiovascular disease.
Methods: Prospective cohort study of asymptomatic HIV positive
men on ART compared to male controls. Baseline demographics, 12
lead ECG, routine biochemistry, NT-proBNP, fasting lipids and
glucose were recorded. Images were acquired on a 3T Achieva Philips
scanner with 5 channel phase array cardiac coil and weight based IV
gadolinium was given at 0.15 mmol/kg dose with post contrast
inversion recovery imaging after 10 min. Controls were age and sex
matched. Philips Viewforum software was used for post processing.
Diastolic function was assessed using phase contrast analysis of mitral
inflow to calculate E:A ratio.
CMR findings: Late gadolinium enhancement (LGE) of the myo-
cardium was found in 5 cases and no controls. In 3/5 cases this was in
a classical infarction pattern with subendocardial involvement. Others
were consistent with prior myocarditis. There was no significant
difference in mean LVEF (66.93 vs. 65.18 %), LVMI(60.05 vs.
55.94 g/m2) or posterolateral wall thickness(8.28 and 8.16 mm)
between cases and controls, respectively. Diastolic dysfunction
determined by E:A ratio\1 was present in 18 % of patients and 7 %
of controls. No patients or controls had Stage III or IV diastolic
dysfunction. There were significant differences in E/A ratio between
cases and controls (p = 0.037). Increasing age, hypertension and
serum triglyceride were predictors for diastolic dysfunction (i.e E/A
ratio \1.0) (p = 0.001, 0.022 and 0.039, respectively).
Conclusion: In our HIV patient population we found an increased
incidence of LGE and diastolic dysfunction compared to age matched
controls (p = 0.03).
Baseline demographics and risk factors
Finding Cases (n = 86) Controls (n = 26)
Mean age (years) 47 ± 9 42 ± 7.8
Current smokers (%) 42 19.2
Hypertension (%) 17 7
Diabetic (%) 6 4
TRIG [2 (%) 27 0
Cocaine use (ever %) 40 7.7
Fam Hx PCAD (%) 25 26.9
TRIG triglyceride level, PCAD premature coronary artery disease
15 Reduced Right Ventricular Myocardial Strain
in the Elite Athlete is not a Consequence of Myocardial
Damage
1King GJ, 2Murphy R, 2Almuntaser I, 1Mc Loughlin B,
1Livingston A, 1Nevin S, 1Clarke JC
1Eagle Lodge Medical Centre, O’Connell Avenue, Limerick;
2St James Hospital Cardiology Department, Dublin
Background: Latest research shows that the lower resting values of
right ventricular %strain may represent a physiologic changes rather
than subclinical myocardial damage [1]. Therefore the aim of this
study is to test this hypothesis.
Methods: Seventeen controls (mean age 27 ± 4), 24 footballers
(mean age 24 ± 4) and 18 elite athletes (mean age 22 ± 4) were
studied. RV% strain were measured using 2D speckle based auto-
mated functional imaging software. RV free wall isovolumic
acceleration (IVA) was measured using pulsed wave tissue Doppler at
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the lateral tricuspid annulus. Standard 2D echo were used to measured
RV parameters including the index Tei (systolic and diastolic func-
tion) and the total annular plane systolic excursion (TAPSE) of the
RV annulus NT-proBNP was measured by an electrochemilumines-
cence assay.
Results: The RV diameter was increased in the footballers and elite
athletes compared to controls (p \ 0.001). RV wall size was greater
in the elite athletes compared to controls and footballers (P = 0.002).
The peak IVA of the RV was higher in the elite athletes, compared to
the footballers and to controls (p \ 0.001). The mean RV% strain
were lower in the elite athletes and the footballers compared to
controls (p \ 0.001). There was no difference in RV Tei index
TAPSE and NT-proBNP across all subjects.
Conclusions: This reaffirms the hypothesis that the reduction in RV%
strain is a physiological response which is counterbalanced by an
increase in acceleration during the isovolumic phase.
Exercise strain rate imaging demonstrates normal right ventricular
contractile reserve and clarifies ambiguous resting measures in
endurance athletes [1].
References
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16 The Use of a Novel Iterative Reconstruction
Algorithm CT to Assess Stable Chest Pain with:
Results from the CAPIR Study
McKavanagh P, Lusk L, Ball P, Trinick T, Duly E, Walls G,
Harbinson M, McQuillan CL, Shevlin S, Alkali M, Donnelly P
Department of Cardiology, Ulster Hospital, Dundonald, Belfast
Aims: The CAPIR study was designed to evaluate the impact of a
novel iterative reconstruction (IR) algorithm on cardiac computed
tomography (CT) image quality and effective radiation dose (ED).
Methods: CAPIR enrolled 250 consecutive patients with suspected
coronary artery disease as a sub-study of the larger CAPP trial, which
was designed to evaluate the implementation of NICE clinical
guideline 95. Cardiac CT examinations were performed on a 64
channel detector CT. Scan protocols were patient specific with ECG
triggering and dose modulation at the clinician’s discretion. Cardiac
data sets were reconstructed with standard filtered back projection
(FBP) or IR technique. Image noise was measured within predefined
regions of interest (ROI), and image quality qualitatively assessed by
two clinicians blinded to the reconstruction method using a 5-point
Likert scale. Effective radiation dose (ED) of each CT was estimated
by multiplying the dose-length product by a chest-specific conversion
coefficient (K = 0.014 mSv 9 mGy-1 9 cm-1).
Results: 4 patients withdrew. 246 patients (140 males) underwent
cardiac CT. 124 consecutively received a routine scanning protocol,
with images reconstructed with FBP (72 with retrospective and 52
with prospective gating). 122 received a reduced tube output (112
with retrospective and 10 with prospective gating) with IR recon-
struction. The mean estimated EDs were 6.5 mSv (FBP) and 4.3 mSv
(IR) (dose savings 34 %) for all patients (p \ 0.00001) and 8.3 mSv
(FBP) and 4.4 mSv (IR) (dose savings 47 %) for the retrospective
cohort. There was no statistical difference in noise or mean attenua-
tion in all three ROIs. The mean IR image quality score was
3.67 ± 1.04 compared to 3.29 ± 1.17 for FBP images (p \ 0.001).
There was also significant agreement between the readers with a mean
Kappa coefficient of 0.83.
Conclusion: IR in cardiac CT offers substantial ED reduction without
compromise in image quality. It is a welcome addition for clinicians
in our attempts to achieve ALARA principles.
17 Impact of Coronary Computed Tomographic
Angiography Results on Patient and Physician
Behaviour in a Low-Risk Population
McEvoy JW, Blaha MJ, Nasir K, Yoon YE, Choi EK, Cho IS,
Chun EJ, Choi SI, Rivera JJ, Blumenthal RS, Chang HJ
John Hopkins Hospital, Baltimore, MD, USA
Background: The impact of screening coronary computed tomo-
graphic angiography (CCTA) on physician and patient behavior is
unclear.
Methods: We studied asymptomatic patients from a health-screening
program. Our study population comprised 1000 patients who under-
went CCTA as part of a prior study and a matched control group of
1000 patients who did not. We assessed medication use, secondary
test referrals, revascularizations, and cardiovascular events at 90 days
and 18 months.
Results: A total of 215 patients in the CCTA group had coronary
atherosclerosis (CCTA positive). Medication use was increased in the
CCTA-positive group compared with both the CCTA-negative (no
atherosclerosis) and control groups at 90 days (statin use, 34 vs. 5 vs.
8 %, respectively; aspirin use, 40 vs. 5 vs. 8 %, respectively), and
18 months (statin use, 20 vs. 3 vs. 6 %, respectively; aspirin use, 26
vs. 3 vs. 6 %, respectively). After multivariable risk adjustment, the
odds ratios for statin and aspirin use in the CCTA-positive group at
18 months were 3.3 [95 % confidence interval (CI) 1.3–8.3] and 4.2
(95 % CI 1.8–9.6), respectively. At 90 days, in the total CCTA group
versus controls, there were more secondary tests [55 (5 %) vs. 22
(2 %); P \ 0.001] and revascularizations [13 (1 %) vs. 1 (0.1 %);
P \ 0.001]. One cardiovascular event occurred in each group over
18 months.
Conclusions: An abnormal screening CCTA result was predictive of
increased aspirin and statin use at 90 days and 18 months, although
medication use lessened over time. Screening CCTA was associated
with increased invasive testing, without any difference in events at
18 months. Screening CCTA should not be considered a justifiable
test at this time.
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18 Community Management of Cardiovascular Risk
in Stage A/B Heart Failure: 6 Month Follow Up
of the Compare-HF Cohort
Horgan S, Tallon E, Dawkins I, Conlon C, Watson C, Baugh J,
Whyte K, Miwa S, McDonald K, Ledwidge M
St Vincent’s University Hospital, Dublin
Background: Current guidelines for heart failure (HF) describe Stage
A/B HF, or pre-HF, as predominantly community dwelling warrant-
ing careful risk factor management. COMPARE-HF evaluates the
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cardiovascular risk factor profile and risk score over 6 months in a
community based population with established Stage A/B HF.
Methods: The Community Programme with Cardiovascular Risk
Evaluation for prevention of HF (COMPARE-HF) population is a
cohort of community patients with a confirmed diagnosis of at least
one of hypertension, diabetes and obesity. We compared blood
pressure (BP), cholesterol, glucose, body mass index (BMI) and
lifestyle risk factors as well as total cardiovascular risk at baseline and
follow-up.
Results: 4296 patients, average age 61 ± 12 years (48.6 % male) with
Stage A/B HF were identified. 68.3, 39.5 and 8.7 % had hypertension,
obesity and diabetes, respectively. 33.3 % were current or ex-smokers,
74.1 % were overweight, 59.8 % took no daily cardiovascular exercise
and 72.9 % consumed alcohol regularly. Normal cholesterol was found
in 43.6 % (population average 5.15 ± 1.15 mmol/L) and 29.7 % had
sitting BP \140/90 mmHg (population average 139.6/82.0 ± 18.9/
10.6 mmHg). Average BMI was 29.0 ± 5.5kg/m2 and average plasma
glucose was 5.75 ± 1.9 mmol/L. Median time to reassessment was
6.2 months (IQR 3.3–12.1). Smoking rates remained unchanged.
Exercise rates and alcohol intake improved modestly. Significant
reductions in BP (-1.5/-1.0 ± 15.7/9.8 mmHg systolic and diastolic,
respectively), cholesterol (-0.29 ± 1.02 mmol/L) and glucose
(-0.06 ± 1.67 mmol/L) were observed (all p \ 0.0001). However,
74.1 % of the population remained overweight, 62.9 % had BP[140/
90 mmHg and 45 % had elevated total cholesterol. Framingham risk
score increased from 6.13 ± 5.77 % at baseline to 6.22 ± 5.88 % at
follow up (p = 0.002).
Conclusion: Cardiovascular risk profile of Stage A/B HF remained
high in this community based risk factor intervention programme.
Programmes such as the on-going STOP-HF study which involve a
shared care approach with specialist support may be needed to modify
the course of Stage A/B HF in at-risk community populations.
19 The Hidden Truth: Stage B Heart Failure Among
Diabetics and Overweight
Murtagh G, O’Connell J, Dawkins I, King T, Griffin J,
Tallon E, O’Hanlon R, Patel A, Ledwidge M, Mc Donald KM
St Vincent’s University Hospital, Dublin
Purpose: Diabetes mellitus (DM) is an independent predictor of heart
failure (HF). The optimal approach to this problem involves identi-
fying patients at risk early in the course of the condition. Previous
studies have shown a high prevalence of diastolic dysfunction in
diabetic subjects. We set out to study the wider burden of structural
and functional problems that could lead to heart failure.
Methods and results: The STOP-HF cohort consists of subjects over
40 with at least one cardiovascular risk factor. Each had a brain
natriuretic peptide level and doppler-echocardiography performed.
Stage B heart failure was defined as structural heart disease [con-
sisting of ejection fraction\50 %, left atrial volume index[34 ml/m2
and/or left ventricular mass index[149 g/m2 (M),[122 g/m2 (F)] in
the absence of symptoms of heart failure. Of 1025 total patients, 234
(22.8 %) were documented as having DM. Prevalence of stage B HF
was 19.8 % in the total population, 23.5 % in those with DM and
18.8 % in the non-diabetic cohort (p = 0.001). Age distribution was
similar across the two groups.
There were 303 patients (33 %) with a BMI[30 kg/m2. Of this obese
cohort, 82 (27 %) had DM. Prevalence of stage B in the obese was
32 % overall. Comparing diabetic obese vs non-diabetic obese, stage
B HF was present in 44 % of the diabetic obese compared to 28 % in
the non-diabetic obese (p = 0.013).
Conclusions: Though asymptomatic, a significant proportion of the
diabetic population had stage B HF, particularly those with BMI
[30 kg/m2. At a time of limited resources, this identifies a cohort of
patients requiring more intensive risk factor control to prevent pro-
gression to symptomatic heart failure.
20 Reduced Absolute Myocardial Blood Flow is
Associated with Worse Diastolic Dysfunction
Groarke JD, Murthy VL, Naya M, Di Carli MF, Shah AM
Brigham and Women’s Hospital, a teaching affiliate of Harvard
Medical School, Boston
Background: Impaired absolute coronary flow in the absence of
perfusion abnormality may reflect coronary microvascular disease and
has been associated with worse prognosis. Whether reduced coronary
flow in the absence of perfusion defects is associated with concom-
itant subclinical abnormalities in contractile function has not been
defined.
Methods: In 122 patients with normal rest and stress perfusion and
ejection fraction by clinically indicated positron emission tomography
(PET), rest myocardial blood flow (MBF) was calculated with factor
analysis and a two-compartment kinetic model. Quantitative analysis
of matched echocardiograms (including strain rate assessment by
myocardial deformational imaging) was performed for parameters of
left ventricular (LV) systolic function: LV ejection fraction (EF), peak
systolic mitral annular velocity (S0), and peak systolic strain rate
(SSR). The correlation between MBF and diastolic parameters was
performed using Pearson correlation.
Results: Mean LVEF was 59 ± 7 %. Rest MBF was not significantly
related to LVEF (p = 0.42). However, lower MBF was significantly
associated with lower S’ (lateral annulus: Pearson correlation coef-
ficient (r) 0.32, p = 0.0007; septal annulus: r 0.21, p = 0.03). Lower
MBF was also significantly associated with worse mean peak longi-
tudinal SSR (r -0.22, p = 0.05).
Conclusions: Lower rest MBF is significantly associated with echo-
cardiographic markers of worse systolic longitudinal function despite
largely preserved LVEF. Future studies should investigate whether
coronary microvascular dysfunction is contributing to the etiology of
subclinical abnormalities in LV contractile function.
21 Diabetic Hearts Show Increased Lysyl Oxidase
Expression
Horgan S, Watson C, Collier P, Ledwidge M, McDonald K, Baugh J
The Conway Institute, University College Dublin, Dublin
Background: Lysyl oxidase (LOX) is a copper-dependent enzyme
that plays a critical role in the biogenesis of connective tissue
matrices. LOX-mediated cross-linking of collagen types I and III
fibrils leads to the formation of stiff collagen and its subsequent tissue
deposition. Evidence from experimental and clinical studies shows
that an excess of LOX is associated with increased collagen cross-
linking and stiffness resulting in cardiac fibrosis and left ventricular
dysfunction. Pre-clinical non-cardiac studies also suggest that LOX
expression is increased in hyperglycaemic states.
Aim: To determine whether LOX expression is increased in the
myocardium of diabetic patients.
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Methods: LOX immunohistochemical analysis was performed on
atrial tissue acquired from 36 patients undergoing cardiothoracic
surgery for ischaemic or valvular heart disease. Quantification of
immunostaining was estimated using a digital image analysis
system (Aperio). LOX staining in diabetic patients was compared
with non-diabetics. LOX gene expression was also determined in
both groups by quantitative real-time polymerase chain reaction
(QPCR).
Results: Five diabetic patients were identified and compared with
the remaining 31 patients in the cohort. Digital image analysis
revealed increased staining intensity for LOX protein in the diabetic
group compared to non-diabetic controls. A significant increase in
strongly positive pixels (p \ 0.05) and a significant decrease in
weakly positive pixels (p \ 0.05) was evident in the diabetic tissue.
QPCR also showed that LOX gene expression is increased in the
diabetic group.
Conclusion: Our findings demonstrate tissue evidence of increased
gene and protein expression of the collagen cross-linking enzyme
LOX in diabetic hearts. We propose that this enhanced LOX activity
may contribute to the development of diabetic cardiomyopathy.
22 Identification of Serum Biomarkers that Reflect
Progressive Cardiac Remodelling
Watson C, Collier P, Horgan S, Conlon C, O’Hanlon R,
Ledwidge M, Baugh J, McDonald K
UCD Conway Institute of Biomolecular and Biomedical Research,
Belfield, University College Dublin, Dublin
Heart failure with preserved ejection fraction (HFpEF) is commonly
preceded by a prolonged asymptomatic phase during which pro-
gressive left ventricular diastolic dysfunction (LVDD) develops.
HFpEF preventative strategies urgently require better biomarkers for
identifying disease manifestations before the onset of symptoms, and
irreversible fibrosis and myocardial damage. In addition, biomarkers
that predict the likelihood and rate of disease progression over time
would help streamline and focus clinical efforts.
To address this we have embarked on a biomarker screening study
to try and identify a serum bio-signal that reflects ventricular dys-
function and heart failure. To date, we have identified a panel of
possible disease-relevant candidates. The work reported herein is a
subcomponent of a prospective study (STOP-HF trial;
NCT00921960), where we are specifically looking at the prognostic
utility of our serum biomarkers in a pre-HF population with risk
factors for the disease.
To investigate the dynamics of our serum biomarker levels with
progressive LVDD, we identified a cohort of 30 subjects from a
population of 518 asymptomatic hypertensive patients from the
STOP-HF trial, whom following serial clinical and echocardiographic
assessment exhibited evidence of progressive left ventricular
remodelling. Progression was based on changes in left atrial volume
index (LAVI). Progressors were identified as those having a change in
DLAVI above a calculated reference change value (C3.5 mls/m2)
from an initial LAVI between 20 and 34 mls/m2. A matched non-
progressor cohort was selected and were similarly identified as those
having DLAVI \3.5 mls/m2. ELISA based serum analysis revealed
that relative changes in MMP9, TIMP1 and LRG, markers of inter-
stitial remodelling and LVDD, tracked with changes in LAVI over
time (all p \ 0.05). This highlights a potential role for these serum
biomarkers in the identification of accelerated changes in LAVI, and
may be a potential aid in highlighting this at-risk group.
23 Assessing Psychological Well-Being in a Population
Undergoing Screening for Inheritable Cardiac Diseases
McQuade C, McShane C, McGorrian C, O’Donnell C,
O’Neill J, Keelan E, Galvin J, Mahon NG, Codd M
Family Heart Screening Clinic, Mater Misericordiae University
Hospital, Dublin
Introduction: Screening for inherited cardiac diseases is recom-
mended in first degree relatives of affected persons. However, this
may be associated with a burden of anxiety in patients undergoing
assessment. We aimed to assess the psychological well-being in such
a screening population and to examine potential associates of
increased psychological distress.
Methods: Prospective cohort study of family members (n = 334)
with a family history of inheritable cardiac disease or a sudden
arrhythmic death syndrome (SADS) bereavement. After providing
informed consent, participants completed two self-reported ques-
tionnaires prior to their clinic visit: (1) the Short Form-12 (SF-12)
Health Survey and (2) the Hospital Anxiety and Depression Scale
(HADS) which provides information regarding patients’ depression
and generalised anxiety. Logistic regression models were used to
examine for associates of a clinically significant HADS score (HADS
C11).
Results: Of 420 eligible patients, 334 provided valid HADS data
(response rate 86.6 %, valid response rate 79.5 %). The mean age was
36.2 years (SD 13.24), with 47.0 % of respondents being male.
Patients attending for SADS screening accounted for 22.2 % of the
population. Almost one in five patients (19.2 %) had a clinically
significant level of anxiety or depression. Factors which confer a risk
for a clinically significant HADS score were female sex, and being a
first degree relative to the proband (vs. second degree or higher).
Protective factors include being married (vs. separated or single), and
having completed education to third level (vs. lower educational
attainment) (Table 1). Indication for screening was not significantly
associated with either of the measures of psychological well-being.
Conclusions: Significant anxiety and depression is present in one-
fifth of patients attending for family heart screening. Clinicians should
be aware of the higher levels of anxiety and depression in females and
consider psychological support on a case by case basis.
Table 1 Simple logistic regression, with a significant HADS score as








Age (in years) 0.99 0.97, 1.01 0.24
Male sex 0.48 0.27, 0.85 0.01
Degree level education vs lower 0.36 0.17, 0.77 \0.01
Marital status: Married vs single/
widowed / divorced
0.49 0.23, 1.03 0.06
Screening reason: SADS vs other
reasons
0.90 0.46, 1.79 0.77
First degree relative to family index
case
2.27 1.13, 4.56 0.02
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24 Long Term Prevention of Recurrent
Cerebrovascular Events with Transcatheter Patent
Foramen Ovale Closure- Findings in Contrast
to the Closure I Trial
Margey R, Elmariah S, Renfigo-Moreno P, Inglessis I, Palacios IF
Structural Heart Disease, Interventional Cardiology and Structural
Heart Disease, Division of Cardiology, Massachusetts General
Hospital, Boston, USA
Background: The role of transcatheter closure of PFO for prevention
of recurrent cerebrovascular events in patients with cryptogenic
ischemic stroke has been questioned with publication of the contro-
versial Closure-1 trial, a prematurely terminated underpowered study
of an inferior closure device.
Aim: We aim to describe the long term outcomes of a single centre
cohort of 805 patients undergoing PFO closure for prevention of
recurrent stroke.
Results: A total of 805 PFO closures were performed. Mean age was
50 years with 52 % male gender. 29.7 % had prior hypertension, 24 %
had prior hyperlipidemia, 10.9 % were current or former smokers,
10.1 % had a family history of vascular disease, 31.3 % had a hyper-
coagulable disorder and 12.1 % had chronic iliac vein compression.
87 % had evidence of right to left shunting, with 56 % having shunting
both at rest and with valsalva manoeurve. 40 % had high risk echo
features with either hypermobile septum or atrial septal aneursym.
Procedural success was 99 %. The most frequently used closure
device was an amplatzer device (38 %), with overall effective defect
closure (defined as complete or minimal residual shunt) in 96 %. At
30 days, 1 death (0.1 %), no stroke, and 1 TIA (0.1 %) occurred. 4
device embolizations occurred (0.5 %), and 18 (2.2 %) patients
developed Afib. In long term follow-up, 8 deaths (1 %), 5 strokes
(0.6 %), 9 TIAs (1.1 %), and 38 (4.7 %) redo PFO closures for residual
shunting occurred, giving an overall MACE (death/TIA/CVA) rate of
2.8 %. Median follow-up was 18 months (range 1 day–15 years).
Conclusions: Transcatheter PFO closure for the prevention of
recurrent stroke can be performed safely with excellent long-term
outcomes, freedom from recurrent stroke or TIA occurring in 98.3 %
of patients at a median follow-up similar to the Closure I trial. These
robust outcomes, better than the Closure-I trial, support our strategy
of independent patient evaluation prior to closure by a multi-disci-
plinary team of neurologists, hematologists, and interventional
cardiologists.
25 Thrombus on Left Atrial Appendage Occluder
Device: Periprocedural Caution
Waterhouse DF, Mehta AG, Abidin NZ, Kennedy MW,
Alqaseer M, Asegom SD, Foley D, McAdam B
Beaumont Hospital, Beaumont, Dublin
Introduction: Atrial fibrillation (AF) is associated with up to 20 % of
ischemic strokes, with the left atrial appendage (LAA) being the main
source of thromboemboli. LAA closure has been shown to be an
effective strategy for thromboprophylaxis. However, the need for
periprocedural anticoagulation following LAA occlusion is often
complicated by the significant anticoagulation risk in this chosen
population. We therefore wished to determine the efficacy of low dose
Dabigatran (110 mg BD) in preventing thrombus formation following
LAA occlusion.
Methods: Thirty-five patients (27 men, 8 women; mean age
74.5 ± 8.2 years) with nonvalvular AF, at high risk for cardioembolic
stroke (mean CHA2DS2VASc score 3.6 ± 1.8) and complications of
oral anticoagulation, underwent percutaneous LAA closure using the
WATCHMAN device. All procedures were performed with fluoros-
copy and transoesophageal echocardiography (TOE) guidance. Follow-
up included clinical and echocardiographic review within 45 days.
Results: The LAA was successfully occluded in 31 patients (97.1 %).
In four cases, device insertion was abandoned due to unsuitable
appendage anatomy. The mean device size was 24.6 ± 3.8 mm. All
procedures were uncomplicated and had no residual flow. Post
WATCHMAN insertion, due to anticoagulation contraindications, 15
patients were given low dose Dabigatran therapy (110 mg BD) rather
than full dose. The 6-week follow up TOE demonstrated mobile
thrombus on the atrial side of the device in four patients treated with low
dose Dabigatran. These patients were subsequently commenced on full
anticoagulation. Subsequent TOE demonstrated full resolution of the
thrombus in all patients. No thrombus was demonstrated in patients
who received Warfarin or full dose Dabigatran anticoagulation.
Conclusion: Our experience revealed that while LAA occlusion is a
safe and successful procedure, the practice of low dose Dabigatran
therapy, before endothelisation of the device, is insufficient in pre-
venting device-related thrombus formation. We suggest that full
anticoagulation should be undertaken for the first 3 months following
implantation.
26 Catecholamine-Induced Heart Hypertrophy:
Impact on Cardiac Function
1Lainis F, 2Buckley MM, 2Johns EJ
1School of Medicine, University College Cork, Cork;
2Department of Physiology, University College Cork, Cork
Background: The impact of experimentally induced heart hypertro-
phy on cardiac haemodynamic parameters and inotropic responses are
not fully understood. We investigated the effects of isoprenaline and
the NO synthase inhibitor NG-nitro-L-arginine (L-Name) on two
groups of Wistar male rats, control versus heart hypertrophy animals.
Methods: Heart hypertrophy was induced by a 2 week regime of iso-
prenaline and caffeine treatment. Nine control and seven heart
hypertrophied male Wistar rats, 220–260 g were anaesthetized by the
administration of 1 ml (ip) of a chloralose/urethane mixture (16.5 and
250 mg/ml, respectively) with supplemental doses of 0.05 ml every
30 min. Cannulae were inserted into the right femoral artery, to monitor
blood pressure and heart rate, and into the right femoral vein for the
infusion of sustaining saline (3 ml/h of NaCl, 9 g/l). Left ventricular
haemodynamics were recorded using a micro-tip pressure tranducer
catheter introduced into the left ventricle via the right carotid artery.
The protocol consisted of bolus injections of a b-adrenoceptor agonist,
isoprenaline 5 lg/ml before and after the infusion of L-NAME, a nitric
oxide synthase blocker a rate of 10 lg/min/kg. The haemodynamic
parameters in the control rats and heart hypertrophied rats were com-
pared using one way repeated measures ANOVA.
Results: The 2 week isoprenaline/caffeine treatment markedly
increased both heart weight and heart weight/body ratio. This was
associated with an increase in maximum dP/dt and contractility index
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of 17 % and 14 % (P \ 0.05), respectively, in the isoprenaline/caf-
feine treated rats. The L-NAME was found to increase the inotropic
effect of the b-adrenoceptor agonist isoprenaline but have no effect on
basal myocyte contractility.
Conclusion: The results indicate that in this model of heart hyper-
trophy cardiac function was increased as reflected by the higher
maximum dP/dt and contractility index. The increases in contractility
index in response to isoprenaline seemed potentiated following
blockade of nitric oxide synthase.
27 Cost Benefit Analysis of Transcatheter Aortic Valve
Implantation (TAVI) Compared to Conventional
Medical Treatment Including Valvuloplasties
in Patients with Severe Aortic Stenosis (AS)
1Neoh S, 2Mahon C, 3Kiat C, 1Galvin B, 2Sugrue R, 3O’Neill C,
1Crowley J, 2Foley B, 2Crean P, 1Sharif F
1University College Hospital Galway; 2St. James’s Hospital, Dublin;
3AMNCH, Dublin
Objective: To evaluate the cost effectiveness of TAVI compared with
conventional medical treatment in patients with severe AS who are
ineligible for surgical AVR. In addition, we also assess Quality of
Life (QOL) and mortality rate between the two groups.
Methods: The research was gathered between Galway University
Hospital (GUH) and St James Hospital. Ethical approval was
obtained from SJH/AMNCH Research Ethics Committee for this
study. In GUH, retrospective chart review were conducted over
2 year period in patients who had severe AS, high risk for AVR
treated with conventional medical treatment (Group 1—42
patients). In St James hospital we enrolled patients who had
TAVI over 2 year period (Group 2—44 patients). For each
patient, we identified the number of admission, Inpatients and
outpatients days, number of Echo, valvuloplasty and TAVI. The
Unit cost was estimated by Casemix. We had also ask to rate
their health status and filled out EQ5DQOL questionnaire. The
costing for this study was performed by employing health tech-
nology assessment.
Results: We enrolled 86 patients with severe AS of whom 42 patients
were treated with conventional medical treatment in GUH and 44
patients were treated with TAVI in St James hospital over 2 year
period (2009–2010). Mean age was 84 years old of whom 53.4 %
were male and 46.5 % were female. As compared with patients
receiving conventional treatment, patients in the TAVI group had an
overall higher total cost, TAVI [(30140 ± 6711) vs. conventional
(15265 ± 15252)], (P = \0.001), however, with lesser readmission
rates TAVI (0.36 ± 1.01) vs. conventional treatment (2.29 ± 1.5),
(P = \0.001) and lower mortality rate (TAVI 9.3 % vs. conventional
treatment 30.9 %, P = 0.010 and 95 % CI 0.0519, 0.3811). In QOL
study, the mean for those who had TAVI was 68.6 % (SD ± 16.2)
whilst the mean for conventional treatment was 56.8 % (SD ± 19.0),
P = 0.015 (95 % CI -21.2, -2.38). Those who had TAVI reported
11.8 %, on average, higher health percentage (QOL) compared with
those who had conventional treatment.
Conclusion: In this study, the total cost of treatment with TAVI was
significantly higher compared with conventional medical treatment
for patient with AS high risk for AVR. However, patient treated with
TAVI has lower readmission rate, significantly lower mortality rate
and better quality of life.
28 Conventional Aortic Valve Replacement Surgery
in Patients not Suitable for Trans-Catheter Aortic
Valve-Outcome Assessment
Beattie R, Booth K, Spence M, Jones MJ
Royal Victoria Hospital, Belfast
Introduction: Patients who are high risk for conventional surgical
aortic valve replacement (AVR) have been offered trans-catheter aortic
valve replacement (TAVI) at our institution since 2008. These patients
are discussed at a multi-disciplinary meeting and those who are refused
on technical or clinical grounds for TAVI may be offered surgical AVR.
Methodology: Data prospectively collected between February 2008
and March 2012 for patients (n = 30) undergoing high-risk AVR
were analysed. Hospital records and national death registry were
searched retrospectively.
Results: 19 patients (63 %) had concomitant coronary artery bypass
grafts, 3 (10 %) had mitral valve surgery, with the remainder solely AVR.
Median age was 83 (range 53–90), mean ejection fraction 46 % with a
mean logistic EuroSCORE of 21.1 %. 3 patients (10 %) had undergone
previous cardiac surgery. Median cross-clamp time was 106 (range
65–233 min) and median bypass time was 143.5 (range 86–359 min).
Major complications seen in the post-operative period included re-ster-
notomy for bleeding (4 patients), renal failure requiring dialysis (1
patient), sternal osteomyelitis (1 patient), permanent pacemaker insertion
(1 patient), and redo AVR for prosthetic valve endocarditis (1 patient).
The median length of hospital stay was 14 days (range 6–51) with no in-
hospital mortality. One-year mortality was 9.5 %.
Conclusion: Conventional open surgery remains a valid option for
high-risk patients in need of aortic valve replacement.
29 Current Demand for Surgery for Rheumatic Heart
Disease in Northern Ireland
Umar Imran Hamid, Alastair Graham
Royal Victoria Hospital, Belfast
Introduction: Rheumatic valve disease is a chronic inflammatory, non-
suppurative complication of pharyngitis that is caused by group
A-hemolytic streptococci. The incidence of rheumatic fever has reduced
significantly in the developed countries and the aim of this study was to
evaluate the current need for surgery for rheumatic valvular disease and
its association with geographical location in Northern Ireland.
Methods: Review of a prospectively maintained cardiac surgery
database was performed. Four hundred and four patients were identified
in the database that underwent valve surgery for rheumatic heart disease
between 2001 and 2011. Demographic details, NYHA class, Euroscore,
in-hospital mortality and nature of surgery were obtained and analysed.
Results: The mean age was 65 years (range 20–86). 297 were female,
107 were male. 331 mitral, 123 aortic and 11 tricuspid rheumatic
valves were operated. The predominant haemodynamic lesion was
stenotic in 44 %, mixed in 36 % and regurgitant in 20 % of the cases.
30 % of patients had previous valve surgery with mean interval to
repeat surgery of 21.5 years (range 1–46 years). A mean of 36 patients
operated each year have an underlying rheumatic valvular disease
(Fig. 1). Distribution of patients operated from various trusts (Fig. 2).
Mean Logistic Euroscore was 9.79. In hospital mortality was 4.7 %.
Conclusions: Despite reduction in the incidence of rheumatic fever to
1 per 100,000 of the population rheumatic valves operated each year
in Northern Ireland remains unchanged in the last decade.
Ir J Med Sci (2012) 181 (Suppl 8):S301–S333 S319
123
Fig. 1 Re-do vs first time valve surgery each year
Fig. 2 Geographical distribution
30 Percutaneous Closure of Patent Foramen Ovale
for Secondary Prevention of Paradoxical Embolus:
Beating the Odds
Galvin M, James S, Waterhouse DF, Abidin NZ, Asgedom SD,
McAdam B, Foley D
Department of Interventional Cardiology and Department of
Interventional Echocardiography, Beaumont Hospital, Dublin
Background: Percutaneous closure of patent foramen ovale (PFO) is
a commonly used method of secondary prevention for patients with
PFO who have had a cryptogenic stroke. Recent data suggests that
PFO closure with a percutaneous device may not offer greater benefit
than medical therapy alone in preventing recurrent stroke or transient
ischaemic attack (TIA). However, this trial reflected PFO closure in
low volume centres, with sites recruiting an average of two patients
per year. We therefore wished to determine whether this intervention
reduces the risk of recurrent stroke in patients with large PFOs,
performed in a large volume center.
Methods: All patients, referred exclusively from neurologist, who
underwent percutaneous closure of PFO as secondary prevention fol-
lowing presentation with presumed paradoxical embolic event over a
5 year period (2006–2011) were included in the study. Main outcome
measures were results of transoesophageal echocardiography (TOE)
6 months post-procedure, recurrence of stroke or TIA during the follow
up period, and death from neurologic causes in the follow up period.
Results: One hundred and fifteen patients (64 male, 51 female; mean age
45 ± 15 years) were included. All procedures were performed under
conscious sedation, with fluroscopic guidance alone. Various devices
were used for closure with mean size 26 ± 4 mm. No significant
procedural complications occurred. All patients were commenced on
dual antiplatelet therapy post-procedure. On follow up TOE 6 months
after implantation, residual shunting was seen in 2.9 %. During a mean
follow up of 20 ± 1 months, only one patient had a further stroke, with
no cases of TIA or peripheral embolic event reported. No patients died
from neurological causes in the follow up period.
Conclusions: The findings of this study, in contrast to recent data, show
that in a high volume centre, with skilled operators, percutaneous closure
of PFO is a safe and effective means of stroke prevention.
31 Incidence of Cardiomyopathy in Heamochromatosis;
are we Cautious Enough?
Khan A, Kaur G, Khan Z, Papaneja N, Quigley C
Wexford General Hospital, Wexford
Hereditary haemochromatosis is a remarkably common condition with
approximately 10–12 % of people of European background being
heterozygous for the condition. It occurs secondary to a fractional
increase in dietary iron absorption resulting in abnormal accumulation
of iron in parenchymal organs, leading to organ toxicity. Cardiomy-
opathy is a major cause of morbidity and mortality in this population.
Objective: The aim of our study was to compare the current local
practice protocols to the European Association for the study of Liver
(EASL) guidelines and identify the incidence of cardiomyopathy in
an Irish population.
Methods: We retrospectively analysed data of all patients enrolled in
the heamochromatosis clinic of a regional medical centre between
2001 and 2010. We recorded demographics, co-morbidities, organ
damage secondary to iron overload, frequency and control of body
iron levels and adherence to international best practice guidelines in
the diagnosis and subsequent management of this patient population.
Results: Data of 101 patients was included in the study. 68 (67.32 %)
were males. An average period of 11.08 months was taken to achieve the
recommended body levels of ferritin. 16 (15.8 %) patients developed
Diabetes while 15 (14.8 %) patients developed arthritis during their fol-
lowup. After multivariate analysis, 34 (33.66 %) of patients were found to
have developed dilated cardiomyopathy secondary to heamochromatosis.
Only 18 (17.8 %) had serial echos done as per the guidelines.
Conclusion: Hemochromatosis is a frequently encountered condition
which needs improved understanding and knowledge of the current
international guidelines. Adherence to international guidelines can
result in early detection and appropriate management of cardiomy-
opathy in patients with heamochromatosis.
32 Non-Cerebrovascular Systemic Arterial Embolic
Events Due to Paradoxical Embolization Via Patent
Foramen Ovale (PFO)
1,2Margey R, 1Elmariah S, 1Hynes BG, 1Renfigo-Moreno P,
2Schainfeld R, 2Jaff MR, 1Inglessis I, 1Palacios IF
1Interventional Cardiology and Structural Heart Disease, Division of
Cardiology, Massachusetts; 2Vascular Medicine, Division of
Cardiology, Massachusetts General Hospital and Harvard Medical
School, Boston, Mass
Background: Paradoxical embolism and cerebral ischemic events via
a PFO has been well described. However, the frequency and clinical
impact of such embolization to other vascular beds is poorly descri-
bed in the current literature.
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Aims: We describe a single center cohort of patients (pts) who presented
with non-cerebrovascular paradoxical emboli, evaluating the relationship
between high-risk PFO features, previously undiagnosed May-Thurner
(chronic iliac vein compression) Syndrome, and hypercoagulability
(cohort 1). We compare this cohort to patients presenting with stroke
(CVA) and/or transient ischemic attack (TIA) (cohort 2).
Methods: 832 patients who underwent transcatheter closure of PFO
between 2001 and 2010 at our institution were retrospectively analyzed.
Demographic, clinical, procedural characteristics plus immediate and
long-term follow-up are summarized. Two-sided T tests and Fishers’
Exact tests were used to compare continuous and categorical variables
cohort 1 and cohort 2.
A total of 832 PFO closures were performed. Cohort 1 included 29 PFO
closures, representing 3.5 % of the overall cohort. There were six acute
myocardial infarctions (MI), nine retinal emboli, six renal infarctions,
three radial artery occlusions, three splenic infarcts, and two lower
extremity arterial emboli. Mean age was 46.4 ± 14 years. Male: Female
ratio 1:1.1. 72 % were not on anti-thrombotic or anti-coagulant therapy at
presentation. 28 % were on aspirin monotherapy. 770 patients are
included in cohort 2. Table 1 summarizes the hypercoagulable and vas-
cular risk factors for the two cohorts. Patients in cohort 1 had shorter PFO
tunnels on transthoracic echocardiography (TTE) (p value), and higher
incidence of both May–Thurner syndrome (p = 0.0001) and hyperco-
agulable disorders (p = 0.07), and were more likely current or former
smokers (p = 0.001). There was no difference in high risk TTE sep-
tum features between the two groups (p = 0.3).





Age mean (SD) 45.6 (± 14) 49.9 (± 13.7) 0.1
Hypertension 27.5 % 29.7 % 0.5
Hyperlipidemia 27 % 24.3 % 0.07
Current or former Smoker 20.5 % 10.9 % 0.001
Family Hx of vascular disease 3.4 % 10.1 % 0.2
Diabetes 3.4 % 5.7 % 0.5
Hypercoagulable Disorder 44.8 % 31.3 % 0.07
Echo Tunnel Length (mm) 7.8 (± 4) 11.2 (± 4.8) 0.03
High Risk Septum features 44.8 % 40.6 % 0.3
May–Thurner Syndrome 44.8 % 12.1 % 0.0001
Effective defect closure was 100 % with no significant residual
shunting. No further arterial embolic events and no further device
embolization occurred. Median follow-up was 376 days (11–2,195 days).
Conclusions: This represents the largest case series of PFO associ-
ated non-cerebrovascular paradoxical emboli. Screening for
hypercoagulable defects and co-existent May–Thurner syndrome in
these cases is warranted due to their high occurrence, higher than seen
in cohort two patients. These patients can be successfully treated with
transcatheter closure, with no recurrent events in follow-up.
33 Trans-Catheter Aortic Valve Implantation: Adverse
Outcomes of 120 Cases in Two Centres
1Sugrue R, 1Teehan S, 1,2Murphy RT, 1Lynch G, 2McCarthy J,
1Tolan M, 2Quinn M, 1Foley B, 1,2Crean P
1Departments of Cardiology and Cardiothoracics, St James’
University Hospital, Trinity College, Dublin; 2Blackrock Clinic,
Dublin
Background and aim: Transcatheter aortic valve implantation is an
alternative in patients with severe aortic stenosis for whom open
surgical valve replacement is not suitable. Procedural mortality has
been described as 0.9–1.5 %, 30-day mortality at 5.4–11.3 % and
mortality at 1 year at 10.3–30.7 %0. In this study, we examined
mortality in all cases of TAVI to date at two centres [1–4].
Methods: Patients who underwent transcatheter aortic valve
implantation (TAVI) were identified from an institutional registry in
two centres. Age, gender and clinical variables were collected. Peri-
procedural complications were recorded. Mortality at time of clinical
follow-up was recorded in both institutions at 30 days, 6 months and
1 year.
Results: There were 120 cases of TAVI from September 2008 to
April 2012 inclusive. The mean age was 81.9 years and the median
82.5 (range 53–95). Males accounted for 59 cases, females for 61.
TAVI was performed transfemorally in 104 cases, transapically in
12 and via subclavian in 3 and transaortic in 1. Femoral access site
complications occurred in nine patients (7.5 %) of which one
required surgical exploration and repair (1.6 %). One patient
developed aortic dissection during the procedure and one died
intraoperatively. Within 30 days of the procedure 7 patients died
(5.8 %). 6 % of patients died with 6 months (6 of 100 patients) and
16.4 % within 1 year (15 of 91 patients). The mean age of those
who died was 84.3 years. Only one person had a transient cere-
brovascular event at 30 days—none had stroke. One patient had a
second TAVI for severe intravalvular and paravalvular aortic
regurgitation 4 months after the initial implant.
Conclusion: In our study the overall mortality at 30 days from 120
TAVI procedures was 5.8 %. The mortality at 1 year from 91 TAVI
procedures was 16.4 % at 1 year. These rates correlate with inter-
national experience to date. At 30 days, no patient had stroke.
References
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34 Radiation Exposure During Transcatheter Aortic
Valve Implantation (TAVI) Procedures
Sharma D, Ramsewak A, O’Conaire S, Spence M, Manoharan G
Royal Victoria Hospital, Belfast
Introduction: Transcatheter aortic valve implantation (TAVI) is a
new alternative treatment for symptomatic aortic stenosis in patients
who are considered high risk or inoperable for conventional surgical
aortic valve replacement. The radiation exposure in these procedures
should be kept as low as reasonably achievable (ALARA). The range
of radiation dose during this procedure is largely unknown.
Methods: Data on radiation exposure was prospectively collected for
consecutive patients undergoing TAVI at our center. The fluoroscopic
and cine-acquisition settings were changed to a lower frame rate
(3.75 frames/s for access site management and 15 frames/sec for
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valve positioning) to assess reduction in radiation doses. We com-
pared the radiation doses in this lower settings (LS) group with
standard settings (SS) group.
Results: Twenty-nine consecutive patients with a mean age of 83
(range 63–91 years); BMI-27.4 (19–42); and 13 males underwent
TAVI using SS between August and December 2011. Twenty-eight
consecutive patients with a mean age of 81(range 64–93 years),
BMI-27.6 (17–44), and 12 males underwent TAVI using LS from
December 2011 to April 2012. The mean dose area product using
the lower setting was 8786 cGy cm2 as compared to 12658 cGy cm2
for the standard group. The screening time [LS: 19.5(14–45) vs. SS:
21 (15–45) min) and procedure time (LS: 110.5 min vs. SS:
120 min) were similar in both groups. The median volume of
contrast used in the LS and SS group were 169 ml and 215 ml,
respectively.
Conclusion: This study demonstrates a significant reduction in radi-
ation dose with the new acquisition settings without compromising
image quality. However, radiation exposure still remains higher
compared to percutaneous coronary interventions due to length and
complexity of this procedure. We are currently evaluating the impact
of using a RADPAD (Worldwide Innovations & Technologies, Inc.,
Kansas, USA) to further reduce radiation dose.
35 Hypertension Patterns Post Aortic Coarctation
Repair
Canniffe C, Walsh K
Mater Misericordiae Hospital, Dublin
Up to 55 % of patients who have undergone aortic coarctation repair
have been shown to develop hypertension, despite anatomically
successful repair. We sought to characterise the patterns of hyper-
tension in this group by assessing office and ambulatory blood
pressure (ABP) measurements in a cohort of our patients.
Methods: An observational study on a retrospective cohort, with
prospective data collection. Patients were identified from clinic logs.
All patients had a right arm office blood pressure (BP) measurement
and a 24 h ABP.
Results: We identified a cohort of 174 patients who attend the Mater
Misericordiae Adult Congenital Cardiac Service who have previously
undergone aortic coarctation repair. So far, 50 % of patients have
been contacted and consented to participate.
To date 34 patients have worn 37 24 h ABP monitors.
Patient characteristics
Descriptive variable
Age—mean [standard deviation (SD)] 30.6 years (10.7)
Male sex (%) 58.8 %
Surgical repair (%) 82.6 %
Stent implantation (%) 17.6 %
Age at primary intervention, median (range) 5 years (0.1–39)
Bicuspid aortic valves 52.9 %
Associated congenital cardiac lesion 17.6 %
Known hypertension (%) 67.6 %
Number of anti-hypertensive agents, mean (SD) 1.26 (1.16)
50 % of patients were found to be hypertensive on right arm office
blood pressure (BP) measurement. The mean systolic BP on office
measurement was 140.1 mmHg (SD 24.27). On ABP measurement
30 % of patients were found to have systolic hypertension. 32.3 % of
patients were found to demonstrate white coat hypertension. 2.9 %
were found to have unmasked hypertension. 38.2 % had a BP load of
[30 %. 23.5 % did not demonstrate a nocturnal dip of 10 % or
greater.
Of those who were found to have systolic hypertension on ABP,
80 % were male. 80 % were already on antihypertensive medications
-mean number of antihypertensive medications 2.57 (SD 0.78).
Conclusion: Recruitment for this study is on-going. We hope to have
enrolled over 120 patients by September 2012. To date, the prevalence
of hypertension in our cohort is comparable to international studies. We
have also found that despite medical therapy a significant proportion of
our cohort had suboptimally controlled blood pressure. Given that
many of the long term complications of aortic coarctation repair are
related to hypertension it is important that we target the management of
BP to improve the long term outcomes of these patients.
36 Perceived Barriers to Exercise in a Cardiovascular
Primary Prevention Programme
Tuohy S, Sharma K, O’Conghaile A, Windle J, Gibson I,
Flaherty G, Crowley J
University College Hospital, Galway
Purpose: Little is known about the barriers for maintenance of
physical activity in a cardiovascular primary prevention programme
in a high risk population. This study aimed to examine perceived
social, psychological, and health-related barriers to the maintenance
of physical activity among participants in a primary prevention pro-
gramme with high cardiovascular risk.
Methods: Data were collected from participants at initiation of the
programme, at the end of the 12-week programme and at 1 year post
completion of the programme to identify perceived barriers to phys-
ical activity. 143 participants (80 male, 63 female) with complete
1 year follow up data were included in the analysis. Additional
objective measurements including anthropometric data, exercise tol-
erance, smoking cessation and anxiety and depression scores were
also evaluated.
Results: Three categories were derived from the stated barriers:
physical, environmental, and psychological. Of the participants 51 %
reported environmental barriers, with 35 % reporting psychological
barriers, and 15 % reporting physical barriers. 64 % of all recorded
primary barriers were overcome throughout the programme. The most
commonly reported barriers were laziness/lack of motivation (28 %),
time (23.8 %) and weather (18.8 %).Females were significantly more
likely than men to overcome their primary barrier (Fisher’s exact test,
p = 0.04).Females were more likely to cite a psychological barrier
while males were more likely to cite an environmental barrier.
Environmental barriers were significantly less likely to be overcome
than physical barriers (Fishers, p = 0.04)
Conclusion: Acknowledgement of barriers to exercise is needed to
guide interventions for promoting physical activity maintenance
among those with high cardiovascular risk. Males experiencing
environmental barriers may need more targeted interventions.
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37 Cigarette Smoking: Association Between
Inflammation, Subclinical Atherosclerosis
and Cardiovascular Events
McEvoy JW, Blaha MJ, Lima JAC, Bluemke DA, Hundley WG,
Min JK, Shaw LJ, Lloyd-Jones DM, Barr RG, Budoff MJ,
Blumenthal RS, Nasir K
Johns Hopkins Hospital, Baltimore, USA
Background: Cigarette smoking is well known to increase the risk of
cardiovascular events. Whether smoking continues to be associated
with adverse events after taking into account the burden of subclinical
atherosclerosis and vascular inflammation is unclear.
Methods: MESA is a population-based study of 6,815 adults free of
baseline cardiovascular disease, recruited from 6 US sites. We strat-
ified participants based on smoking status into 3 groups: Never (NS),
former (FS), and current smokers (CS). FS and CS were further
stratified into quartiles of pack-year history of tobacco exposure
(PYH). We excluded 28 participants with missing information on
smoking (n = 23) or follow-up events (n = 5). We analyzed the
association of smoking status with coronary heart disease (CHD) and
cardiovascular disease (CVD) events after taking into account tradi-
tional risk factors, CRP, as well as burden of CAC.
Results: A total of 6787 participants were followed for median
5.8 years. CS comprised 887 (13 %, mean age 58 years), FS 2484
(37 %, 63 years) and NS 3,416 (50 %, 62 years). Significantly more
CS suffered both CHD and CVD events than NS [4.5 vs. 3.3 %
(p = 0.003) and 6.5 vs. 4.9 % (p = 0.019), respectively]. Multivari-
able HRs of 1.8 (CHD, p = 0.004) and 1.9 (CVD, p \ 0.001) were
found in CS, compared to NS. These findings were increased with
higher PYH, suggesting a dose–response effect of smoking on events.
Incremental reductions in these HRs were found on addition of CRP
(e.g. CVD HR = 1.8, p \ 0.001) and then CAC (e.g. CVD
HR = 1.5, p = 0.012) to the multivariable adjusted regression model.
No differences in event HRs were found between FS and NS.
Conclusions: CS, but not FS, was strongly associated with events. This
association weakened slightly with the inclusion of CRP, and more
significantly with the inclusion of CAC. However, the persistent asso-
ciation of smoking with events even after accounting for the burden of
inflammation and CAC confirms the importance of additional pathways
contributing to the cardiovascular risk associated with smoking.
38 Impact of a Phase 2 Cardiac Rehabilitation
Programme on Exercise Performance Across Patient
Subgroups: Who Benefits Most?
Neylon A, McGorrian C, Gallagher A, Murphy A, Blake G,
Mahon N, McCann H, Sugrue D
Department of Cardiology, Mater Misericordiae University Hospital,
Dublin
Introduction: An important component of cardiac rehabilitation (CR)
programmes is exercise training. Improvements in aerobic exercise
capacity are associated with reduced cardiac and all-cause mortality
in patients who have suffered a myocardial infarction (MI). We aim to
describe the impact of an Irish Phase 2 CR programme on exercise
performance in patients with coronary artery disease (CAD).
Methods: This was an audit study of prospectively collected data on
consecutive patients with CAD referred for CR from 2003 to 2011
inclusive. Data were gathered on baseline demographics, indications
for referral, treadmill test type and treadmill test total metabolic
equivalents of task (METs) pre- and post-CR. A change score for
post-CR METs was calculated, and differences in means were com-
pared using the Student’s t test and ANOVA. Analyses were
performed using Stata 9 statistical software.
Results: In total, 3187 patients with CVD were referred for CR, with a
programme participation rate of 57 % (n = 1825). Mean age was
62.9 years (SD 11.9). Mean METs pre-CR were 7.01 (SD 2.96),
compared with 8.91 (SD 3.15) post-CR (p \ 0.005). The mean increase
in METS was greatest in men (mean change in METs 2.13 (SD 1.85) vs
1.58 (SD 1.58) in women; p \ 0.005). Patients post CABG had a
greater improvement in exercise capacity than those post MI/PCI (mean
change in METs 2.18 (SD 1.68) in CABG vs. 1.97(SD 1.81) in MI
group; p \ 0.036). A statistically significant inverse association was
noted between change in METs and increasing age group (p \ 0.001).
Nevertheless, even in participants aged over 75 years (n = 173), a
mean increase in METs of 1.69 (SD 1.55) was observed.
Conclusion: We observed an increase in exercise capacity across all
patient groups participating in phase 2 CR. Improved METS in older
patients underline the benefits of encouraging all eligible patients to
attend a CR programme.
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39 Patients with Hypertension and Heart Failure
with Preserved Ejection Fraction Present with Elevated
Inflammatory and Alternative Monocyte/Macrophage-
Apecific Markers in their Peripheral Circulation
Glezeva N, Voon V, Watson C, Ledwidge M, McDonald K,
Baugh J
Conway Institute, University College Dublin, Dublin
Introduction: Inflammation contributes to the pathophysiological
myocardial remodelling in early and late heart disease. A progressive
state of immune-inflammatory activation and fibrosis with increased
monocyte activation and infiltration into cardiac tissue has been associ-
ated with the progression to LVDD and HF. Monocytes are main
regulators of host immunity, tissue inflammation and remodelling. Three
monocyte subtypes exist: classical inflammatory (CD14??CD16-);
intermediate(CD14?(?)CD16?); and alternative anti-inflammatory,
fibrotic/healing(CD14?CD16??) monocytes. Monocytes differentiate
into inflammatory (M1) or regulatory/pro-fibrotic (M2) macrophages.
Alternative monocytes and M2 macrophages have been separately
implicated in the pathogenesis of vascular inflammatory diseases
including atherosclerosis, MI, CAD, HF, myocarditis, stroke. It was
suggested that macrophage polarization to M1/M2 depends on the
expression pattern of specific monocyte markers and cytokine mediators.
Method: We analysed monocytes from patients at different stages of
heart disease and associated peripheral blood markers to disease
pathogenesis.
Peripheral blood was collected from 83 patients with asymptomatic
hypertension (aHTN), LVDD, and HFPEF. Echocardiography was
performed on all patients. PBMC and monocytes were purified and
stained for CD14, CD16, CD163, CD206. Inflammatory cytokines in
plasma were identified.
A progressive state of inflammation in LVDD and HFPEF
compared to aHTN was defined by elevated peripheral levels of TNFa
(2.26–2.15–3.10 pg/ml), IL12 (80–81–117 pg/ml), IL6 (2.7–3.8–4.8
pg/ml), MCP1 (186–186–230 pg/ml). These also correlated with
peripheral BNP. Levels of M2-associated cytokines were also
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increased: CCL17 (49–49–65 pg/ml), CCL18 (8.8–10.2–12.3 pg/ml),
sCD163 (470–488–579 ng/ml). Percentage of CD14? monocytes was
higher in aLVDD and HFPEF (13–19–21 %) and overlapped with
increased numbers of CD14??CD16- and CD14?CD16?? mono-
cytes. Monocytes expressing the M2 markers CD163 and CD206
were also increased in HFPEF.
Results: We identified increased numbers of pro-inflammatory
monocytes and elevated M2-associated regulatory and fibrotic
markers in peripheral plasma and monocytes of asymptomatic LVDD
and HFPEF patients.
Conclusion: We suggest an increased activation and differentiation of
monocytes towards regulatory, pro-fibrotic M2 macrophages occurs
in early heart disease and these changes are associated with pro-
gression to HFPEF.
40 A Novel Biomarker and Potential Treatment
for Diastolic Dysfunction and Heart Failure
Horgan S, Watson C, Collier P, Ledwidge M, McDonald K,
Baugh J
The Conway Institute, University College Dublin, Dublin
Purpose: Heart failure with preserved ejection fraction (HFPEF)
contributes to 20–50 % of the heart failure population. Excessive
myocardial fibrosis results in stiffness and reduced compliance of the
left ventricle which leads to left ventricular diastolic dysfunction
(LVDD) and eventual HFPEF. We investigated the role of *HU1001,
an innate immune system recognition molecule, as a biomarker for
LVDD and HFPEF, and assessed its potential as a treatment for
cardiac fibrosis.
Methods: For biomarker analysis, a cross sectional study of patients
with asymptomatic hypertension (AH) and HFPEF, and a prospective
study of patients with asymptomatic progressive LVDD were carried
out (n = 140 patients). The anti-fibrotic potential of HU1001 was
tested in an animal model of hypertensive heart disease. Three groups
of 10 animals were studied including group 1: normotensive Wistar-
Kyoto rats treated with vehicle (V-WKY), group 2: spontaneously
hypertensive rats treated with vehicle (V-SHR) and group 3: SHRs
treated with recombinant HU1001 (HU1001-SHR). Duration of
treatment was 12 weeks.
Results: HFPEF patients had significantly lower (p = 0.0003)
HU1001 levels than those with AH. HU1001 concentration was also
found to decrease over time in patients with progressive LVDD
(p \ 0.05). Negative correlations between HU1001 and a number of
fibro-inflammatory markers were present. Compared with V-WKY,
V-SHR exhibited significant increases in left ventricular mass index
(LVMi) and perivascular collagen index (PVCi). HU1001 adminis-
tration was associated with a significant reduction in both LVMi
(p \ 0.0001) and PVCi (p = 0.0016). There was also a significant
reduction in the neutrophil and monocyte chemotactic proteins
CXCL-1 (p \ 0.05) and MCP-1 (p \ 0.001).
Conclusions: HU1001 levels become depleted in more severe disease
states and track the progression of LVDD. Treatment with HU1001
inhibits deposition of PVC and reduces LVM in SHRs. Lower che-
motactic protein concentrations found in HU1001 treated animals
may reflect the ability of this peptide to prevent recruitment of pro-
fibrotic macrophages.
*Note from author:
I have submitted this abstract based on research I am currently
undertaking. My research group are currently filing for a patent on the
protein I describe in the abstract. As a result, I have been advised to
use the codename HU1001. The patent will be through well in
advance of the Irish Cardiac Society meeting when we will be in a
position to disclose the name of the protein. I apologise for this
inconvenience.
41 Carotid Intima-Media Thickness Independently
Predicts Significant Coronary Artery Disease and is
as Good as a Bank of Novel Risk Markers
Leong T
Adelaide and Meath Hospital, Tallaght, and St. James’s Hospital,
Dublin
Background: Cardiovascular disease (CVD) remains the leading
cause of death worldwide. Identification of those at increased risk can
be improved, possibly through novel risk markers, or by tests such as
carotid intima media thickness (CIMT) assessment.
Methods: The Cath Lab Study was an originally designed study
which recruited 730 stable patients undergoing coronary angiography
with chronic stable angina, suspected coronary artery disease (CAD)
or for valve surgery. Of these, 386 had simultaneous CIMT assessed,
and they comprised this study arm population. Significant CAD was
defined using the SYNTAX score (C1 vs. 0). Raised CIMT (CIMT-
75) was defined as[75th percentile cut-points of the ARIC study, as
suggested by ASE guidelines. Laboratory assays for novel risk
markers were Roche (hs-CRP), Abott IMX (homocysteine) and R&D
Systems (CD40 ligand, VCAM and P-selectin).
Results: There was a significant graded association between CIMT
and blood pressure, hypercholesterolaemia and smoking, as well as
the novel risk markers VCAM, P-selectin and homocysteine, Signif-
icant univariate correlations with CIMT included: age (r = 0.37,
p \ 0.0001), male sex (r = 0.19, p = 0.0002), systolic BP (r = 0.19,
p = 0.0002), hypercholesterolemia (r = 0.12, p = 0.02), smoking
(r = 0.11, p = 0.02), glucose (r = 0.14, p = 0.006), the metabolic
syndrome (r = 0.18, p = 0.0005), homocysteine (r = 0.20,
p = 0.0001), log CD40 ligand (r = 0.11, p = 0.03), VCAM
(r = 0.11, p = 0.04), P-selectin (r = 0.14, p = 0.01). Table 1 shows
the OR of significant CAD for CIMT-75 adjusted for Models 1 and 2
(all the traditional risk factors), and Model 3, also including the bank
of novel risk markers (hs-CRP, homocysteine, CD40 ligand, VCAM
and P-selectin). Tests of likelihood ratio between Models 2 and 3
showed no significant improvement of fit (p = 0.55). CIMT-75 has a
high negative predictive value (88 %).
Conclusions: CIMT-75 can independently predict significant CAD
defined using a prognostically significant score. CIMT-75 is as good





95 % CI P value
CIMT-75 (univariate) 7.8 2.3, 26.8 0.001
Model 1: CIMT-75—adjusted for
conventional risk factors: age,
sex, blood pressure and smoking
6.3 1.2, 34.0 0.03
Model 2: CIMT-75—adjusted also
for other traditional risk factors:
HDL cholesterol, glucose
6.2 1.2, 33.3 0.03
Model 3: CIMT-75—adjusted also
for novel risk markers: hs-CRP,
homocysteine, VCAM, P-selectin,
fibrinogen and log CD40 ligand
4.5 0.8, 25.7 0.09
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42 Cardiovascular Magnetic Resonance of Myocardial
Edema Using a Short Inversion Time Inversion
Recovery (Stir) Black-Blood Technique: Diagnostic
Accuracy of Visual and Semi-Quantitative Assessment
1O h-Ici D, 2Ridgway JP, 1Kuehne T, 1Berger F, 3Plein S,
4Sivananthan M, 1Messroghli DR
1Department of Congenital Heart Disease and Pediatric Cardiology,
Deutsches Herzzentrum Berlin, Augustenburger Platz 1, Berlin
13353, Germany;2Medical Physics, Leeds General Infirmary, Great
George Street, Leeds UK; 3Leeds Institute, UK
Background: The short inversion time inversion recovery (STIR)
black-blood technique has been used to visualize myocardial edema, and
thus to differentiate acute from chronic myocardial lesions. However,
some cardiovascular magnetic resonance (CMR) groups have reported
variable image quality, and hence the diagnostic value of STIR in routine
clinical practice has been put into question. The aim of our study was to
analyze image quality and diagnostic performance of STIR using a set of
pulse sequence parameters dedicated to edema detection, and to discuss
possible factors that influence image quality. We hypothesized that STIR
imaging is an accurate and robust way of detecting myocardial edema in
non-selected patients with acute myocardial infarction.
Methods: Forty-six consecutive patients with acute myocardial
infarction underwent CMR (day 4.5, ?/1.6) including STIR for the
assessment of myocardial edema and late gadolinium enhancement
(LGE) for quantification of myocardial necrosis. Thirty of these
patients underwent a follow-up CMR at approximately 6 months (195
?/39 days). Both STIR and LGE images were evaluated separately on
a segmental basis for image quality as well as for presence and extent of
myocardial hyper-intensity, with both visual and semi-quantitative
(threshold-based) analysis. LGE was used as a reference standard for
localization and extent of myocardial necrosis (acute) or scar (chronic).
Results: Image quality of STIR images was rated as diagnostic in
99.5 % of cases. At the acute stage, the sensitivity and specificity of
STIR to detect infarcted segments on visual assessment was 95 and
78 %, respectively, and on semi-quantitative assessment was 99 and
83 %, respectively. STIR differentiated acutely from chronically
infarcted segments with a sensitivity of 95 % by both methods and with a
specificity of 99 % by visual assessment and 97 % by semi-quantitative
assessment. The extent of hyper-intense areas on acute STIR images was
85 % larger than those on LGE images, with a larger myocardial salvage
index in reperfused than in non-reperfused infarcts (p = 0.035).
Conclusions: STIR with appropriate pulse sequence settings is accurate
in detecting acute myocardial infarction (MI) and distinguishing acute
from chronic MI with both visual and semi-quantitative analysis. Due to
its unique technical characteristics, STIR should be regarded as an edema-
weighted rather than a purely T2-weighted technique.
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43 Impact of Stent Overlap on Long-Term Clinical
Outcome in Patients Undergoing Newer-Generation
Drug-Eluting Stent Implantation
O’Sullivan CJ, Stefanini GG, Pilgrim T, Ra¨ber L, Taniwaki M,
Bu¨llesfeld L, Khattab AA, Nietlispach F, Wenaweser P, Meier B,
Windecker S
Swiss Cardiovascular Centre, Bern University Hospital, Bern,
Switzerland
Objectives: We compared the long-term clinical outcomes of patients
with and without overlap of first generation and newer generation
drug-eluting stents (DES).
Background: First-generation DES overlap is associated with
impaired angiographic and long-term clinical outcomes, including
death or myocardial infarction, but the impact of newer generation
DES overlap on long-term clinical outcome is unknown.
Methods: We analyzed the clinical outcomes of 3,133 patients treated
with DES [1,532 patients treated with sirolimus eluting stents (SES)
and 1,601 patients treated with everolimus eluting stents (EES)] in the
Long-term comparison of Everolimus-eluting and Sirolimus-eluting
Stents for coronary revascularization (LESSON) trial according to the
presence or absence of stent overlap and the number of stents per
vessel: 969 (30.9 %) patients with multiple DES in a vessel with
overlap, 446 (14.2 %) patients with multiple DES in a vessel without
overlap, and 1,718 (54.8 %) patients with 1 DES per vessel. The
primary outcome was a composite of death, MI, and target vessel
revascularization.
Results: The primary endpoint of death, myocardial infarction (MI)
and target vessel revascularization (TVR) was more common overall
in patients with DES overlap (207 events, 25.1 %) than in the other
groups (80 events, 20.8 % and 280 events, 18.8 %) at 3 years
(p \ 0.001). This was largely driven by a higher incidence of the
primary endpoint in the SES overlap group (102 events, 28.7 %)
compared with the other SES groups (49 events, 22.6 % and 147
events, 17.6 %) at 3 years (p \ 0.001). There was no significant
difference in the primary endpoint when comparing EES overlap (105
events, 22.3 %) with the other EES groups (31 events, 18.5 % and
133 events, 20.4 %) at 3 years (p = 0.32).
Conclusions: The unrestricted use of EES overlapping stents is
associated with improved long-term clinical outcomes when com-
pared with SES overlapping stents.
44 Contemporary Predictors in Successful PCI
of Chronic Total Occlusions
Leong T
Institut Cardiovasculaire Paris Sud, Paris, France
Background: Percutaneous Coronary Intervention (PCI) of CTOs
remains relatively infrequent partly due to the challenging nature and
paucity of data on the likelihood of success. Newer techniques are
also available which may improve success. We sought to examine
factors in order to improve patient selection and optimisation of
conditions for success.
Results: Of 1,508 consecutive PCIs of CTO in our institution per-
formed between January 2004 to January 2012, the success rate was
71 %. The characteristics of our study population were: median age
63, male 86 %, ACS 13 %, mean creatinine 98 lmol/L, previous
CABG 8 %, previous MI 23 %, previous PCI 39 %, radial 82 %,
mean procedural duration 92 min, mean X-ray dose 41 Gy cm2, mean
contrast dose 280 ml, vascular complications 0.4 %, serious bleeding
0.06 %. Significant univariate correlations for successful PCI were
tapered morphology (r = 0.1, p = 0.0001), intraluminal bridge
(r = 0.14, p = 0.002), operator experience (r = 0.07, p = 0.01),
rotablator use (r = 0.08, p = 0.002), retrograde approach (r = 0.07,
p = 0.01), while factors that contributed to failure were age (r =
-0.06, p = 0.02), lesion length (r = -0.17, p \ 0.0001), no visible
stump (r = -0.08, p = 0.002), calcification (r = -0.15, p \ 0.0001),
proximal tortuosity (r = -0.06, p = 0.02), previous MI (r = -0.1,
p = 0.0001), previous CABG (r = -0.12, p \ 0.001). Table 1 shows
selected factors in terms of their odds ratios of successful PCI of CTO
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in a multivariable logistic model adjusting for the traditional pre-
dictors, other anatomical characteristics, clinical factors and lastly
newer techniques. The model included age, sex, lesion length, cal-
cification, stump visibility, tapered morphology, proximal tortuosity,
intraluminal bridge, previous MI, previous CABG, and technical
considerations such as operator experience, radial approach, femoral
approach, and other techniques.
Conclusions: In this contemporary series, the traditional predictors of
lesion length, calcification, stump visibility, tortuosity still hold true,
even when other newer significant factors such as intraluminal bridge,
previous MI, previous CABG, operator experience and other newer
techniques are taken into account.
45 Long-Term Clinical Outcomes of Percutaneous
Coronary Intervention with Drug-Eluting Stents
in Patients with Mechanical Heart Valves
O’Sullivan CJ, Moschovitis A, Zanchin T, Stortecky S, Stefanini GG,
Pilgrim T, Ra¨ber L, Taniwaki M, Bu¨llesfeld L, Khattab AA,
Nietlispach F, Wenaweser P, Meier B, Windecker S
Swiss Cardiovascular Centre, Bern University Hospital, Bern,
Switzerland
Aims: Clinical outcomes following percutaneous coronary revascu-
larization (PCI) with the unrestricted use of drug-eluting (DES) stents
in patients with mechanical heart valve prosthesis (MP)—requiring
life-long oral anticoagulation—have not been previously described.
We sought to investigate long-term clinical outcomes of PCI with
DES in patients with MP.
Methods and results: Among 6,308 consecutive patients undergoing
PCI with DES, 41 patients (0.7 %) were taking oral anticoagulation at
baseline because of a previously implanted MP [aortic position: 28
(68 %), mitral position: 13 (32 %)] and were prospectively followed up to
4 years in the Bern DES registry (mean duration of follow-up
3.0 ± 1.6 years, no patients were lost to follow-up). All patients were
discharged on triple anthithrombotic therapy—comprising aspirin, clop-
idogrel, and oral anticoagulation—for a minimum period of 3 months,
after which clopidogrel was stopped. Our pre-specified primary endpoint
was a composite of all-cause mortality, myocardial infarction, ischemic
stroke, or bleeding type 3 and 5 according to the guidelines by the aca-
demic research consortium (BARC). Mean age at baseline was
70.5 ± 8.8 years, 24.4 % of patients were female. Indication for PCI was
an acute coronary syndrome in 29.3 % of patients. 90.2 % patients and
95.1 % of patients were discharged on aspirin and clopidogrel, respec-
tively. The primary endpoint was observed in 16 patients (39.0 %) at
4 years. All-cause mortality and myocardial infarction occurred in 11
(26.8 %) and 2 (4.8 %) patients, respectively. Three patients (7.3 %) had
BARC bleeding type 3/5, two of which occurred on the day of the index
PCI. One patient (2.4 %) suffered an ischemic stroke. No definite stent
thrombosis occurred during the observed period.
Conclusion: Despite a high risk of adverse outcome, the unrestricted
use of DES among patients with MP was associated with modest rates
of significant bleeding events.
46 Radial Artery Occlusion
Dooley M, Spence M, Roberts M
Belfast Health and Social Care Trust, Belfast
Aim: To identify Radial Artery Occlusion (RAO) rates in patients
attending for coronary angiography (CA) ± percutaneous coronary
intervention (PCI) via transradial access.
Background: Radial artery cannulation caries a risk of RAO with an
incidence of 1–19 %. This is usually of no clinical consequence,
because the hand receives a dual blood supply with extensive col-
lateral channels but it limits future use of transradial access, radial
graft for CABG, AV fistula formation. Known risk factors for RAO
are radial artery:sheath ratio, inadequate anticoagulation, conven-
tional vs perfused haemostasis, female gender, low body weight, short
procedure and younger age.
Methods: Patient Inclusion criteria: transradial access for CA ± PCI,
all comers. No exclusion criteria.
• Pre-procedure:
• Patient information data set obtained, radial artery assessed by
palpable pulse and plythesmography (Barbeau’s test).
• Post procedure (\ 24 h):
• Procedural and haemostasis data set obtained. Radial artery
assessment repeated.
Results:
RAO in 14 patients (n = 51).
Patient information:
Median age 68 IQR (60–75) patent, 56.5 IQR (49–63) in occluded.
Female 27 % RAO, Male 26.5 % RAO. Smokers (n = 9): 66 %
RAO. Median weight 80 kg IQR (70–88) patent, median 93 kg IQR
(75–102) RAO.
Procedure information:
Sheath size 5F (n = 15) 33 % RAO, 6F (n = 35) 26 % RAO and
7F (n = 1) 0 % RAO.
Heparin use median 2000u in RAO (vs. 5000 in patent), if received
\5,000 U (n = 18) 50 % had RAO. Procedure time median 40 min
IQR (24–70) in patent, median 25 min IQR(19-43) in RAO. PCI





95 % CI P value
Age (per 5 years increase) 0.91 0.85, 0.97 0.004
Lesion length (per 5 mm
increase)
0.87 0.84, 0.91 \0.001
Calcification 0.79 0.69, 0.92 0.002
No visible stump 0.69 0.49, 0.98 0.036
Proximal tortuosity 0.65 0.46, 0.98 0.02
Intraluminal bridge 2.07 1.31, 3.27 0.002
Previous MI 0.62 0.46, 0.86 0.003
Previous CABG 0.39 0.24, 0.64 \0.001
Operator experience
(per 50 cases increase)
1.16 1.08, 1.25 \0.001
Radial access 1.45 0.91, 2.30 0.11 (NS)
Anchoring balloon 1.97 1.15, 3.35 0.013
Tornus catheter 1.48 0.55, 3.96 0.44 (NS)
CART technique 3.7 0.6, 22.6 0.16 (NS)
Mother-and-child cath 15.0 1.3, 174.6 0.03
Retrograde wire 7.4 2.2, 24.9 0.001
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Median 15 mls of air in TR Band. Initial inflation duration median
60 min IQR (30–120) RAO, 74 min IQR (50–120) in patent. Total
inflation duration median 132 min IQR (120–210) RAO, 224 min
IQR (150–300) in patent.
Conclusion: At 27.4 % within 24 h post procedure the RAO rate was
higher than expected. Although at 30 days this figure would be
reduced by recannulation improvements can be made principally
through adequate heparin use.
47 Optical Coherence Tomography (OCT) Guided
Assessment of Coronary Intervention
Hillery P, Waterhouse DF, Abidin NZKZ, Asgedom SD, McAdam B,
Foley DP
Beaumont Hospital, Beaumont, Dublin
Introduction: Optical coherence tomography (OCT) is an optical analog
of intravascular ultrasound (IVUS) that may be used to examine the
coronary arteries and has tenfold higher resolution than IVUS. OCT
allows tissue differentiation (fibrous, calcified, or lipid-rich plaque) and
may identify of plaques that have been associated with rapid lesion pro-
gression and clinical events. Following percutaneous coronary
intervention, OCT facilitates assessment of stent positioning, stent strut
coverage and in-stent stenosis. In this study, we wished to determine the
role for routine OCT assessment following percutaneous coronary
intervention (PCI) and the clinical impact of such a strategy.
Methods and results: All patients presenting for both emergent and
PCI of a native coronary stenosis, and suitable for OCT imaging were
included (n = 132). All patients underwent OCT post coronary inter-
vention (mean 45 days). The incidence of stent malposition was 17.4 %
(n = 23). In 28 patients, the stents were covered completely with neo-
intima. OCT demonstrated underexpanded stent struts in 23 patients.
Following OCT, 59 patients underwent further coronary interventions.
Most commonly the OCT findings leading to further intervention were
stent malaposition, plaque prolapse and edge dissection.
Conclusion: OCT is a novel, promising imaging modality. The
findings of this study demonstrate that OCT may impact clinical
outcomes in patients who have undergone coronary intervention.
48 The Changing Profile of Patients Undergoing Urgent
Coronary Artery Bypass Surgery in the Primary
Percutaneous Intervention Era
Beattie R, Wilson C, Graham ANJ
Royal Victoria Hospital, Belfast
Aims: Primary percutaneous intervention (PPCI) was introduced in
the Belfast Trust in December 2009, providing a round-the-clock
regional service for patients presenting with acute myocardial
infarction. In addition, publication of the results of the Syntax study
may have influenced treatment strategies. We aimed to investigate if
these factors have altered the profile of patients requiring urgent and
emergency coronary artery bypass grafting.
Methods: The cardiac surgical database was searched retrospectively
for all patients undergoing urgent, emergency or salvage isolated
coronary artery bypass grafting in the period 2008–2009 (2 years
preceding the introduction of PPCI) and 2010–2011 (2 years fol-
lowing). Patient characteristics, intraoperative and post operative data
were compared between the two groups using both student t test and
Chi squared statistical analysis.
Results
Period Operative priority Total
Elective Urgent Emergency Salvage
2008–2009 667 328 30 1 1,026
2010–2011 665 299 16 1 981
In the 2010–2011 period there was a decrease in the number of
non-elective CABG cases (359 vs. 316). There was an increased
proportion of male patients (2008–2009: 74.4, 2010–2011: 82.6 %;
p = \0.01), with lower EuroScore (12.12, 9.46; p = \0.01), CCS
(mean 3.24, 2.73; p = \0.01) and NYHA classes (2.32, 2.03;
p = \0.01). Preoperative inotropic, ventilator or balloon pump
requirements were not significantly different. Although no significant
difference was seen in left main stem disease (57.9, 60.5 %;
p = 0.50), patients had more extensive coronary disease (mean
number of vessels involved 2.72 vs. 2.82, p = 0.01). This was
reflected in the increased cross clamp (62.4 and 68.1 min, p = \0.01)
and bypass times (111.3 and 120.1 min, p = 0.01).
Conclusion: The introduction of a PPCI service has been associated
with a reduction in urgent and emergency CABG surgery in our unit.
Patients requiring surgery are now less symptomatic with reduced
operative risk but with more extensive coronary disease.
49 Myocardial Tissue Hypoxia is Associated
with Changes in the Epigenome
Watson C, Neary R, Collier P, Tolan M, Ledwidge M,
McDonald K, Baugh J
UCD Conway Institute of Biomolecular and Biomedical Research,
Belfield, University College Dublin
Prolonged ischemia caused by coronary artery disease and myocardial
infarction leads to aberrant ventricular remodelling and cardiac
fibrosis. This is thought to occur through the accumulation of gene
expression changes in resident fibroblasts, resulting in an overactive
fibrotic phenotype. Long term adaption to this hypoxic insult is likely
to require significant modification of chromatin structure in order to
maintain the fibrotic phenotype. We propose that epigenetic modifi-
cations play an important role in dictating hypoxia-induced fibrosis
within the heart. Therefore, the purpose of this study was to investigate
whether a hypoxic environment within cardiac tissue was associated
with epigenetic changes and an enhanced fibrotic phenotype.
For this study, myocardial tissue was procured from 36 stable
patients undergoing elective cardiothoracic surgery. Specimens were
obtained adjacent to the venous cannulation site in the right atrial
appendage. All subjects gave written informed consent to participate
in the study. The relationship between the degree of hypoxia, DNA
methylating enzymes, and collagen 1 were investigated using quan-
titative real-time PCR (QPCR). Carbonic anhydrase IX (CAIX)
expression was used as a surrogate marker of hypoxia. Immunohis-
tochemical staining of cardiac tissue was used to study the
relationship between tissue regions of hypoxia (CAIX protein posi-
tivity) and levels of DNA methylation (nuclear 5MeC positivity). A
positive pixel count algorithm (Aperio) was used to quantify the
intensity of positive immuno-staining.
Results obtained provide ex vivo evidence in cardiac tissue that
hypoxia is associated with an altered epigenetic landscape. The
degree of tissue hypoxia (CAIX levels) significantly correlated with
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collagen 1 and DNA methyltransferase 3B gene expression. Hypoxic
regions within cardiac tissue (CAIX positive) were associated with
regions of DNA hypermethylation.
Whether or not these changes in DNA methylation are required
for maintaining a viable hypoxic phenotype, or whether they are
directly involved in the enhanced fibrotic response requires further
investigation.
50 Refining Transcatheter Left Atrial Appendage
Closure: Eliminating the Anaesthestist and Reducing
the Cost
Waterhouse DF, Kennedy MW, Asgedom SD, Neylon A,
Alqaseer M, McAdam B, Foley DP
Department of Cardiology, Beaumont Hospital, Dublin
Introduction: The validity and benefit of LAA closure for throm-
boembolic prevention in non-valvular AF is well established. To date,
all studies for this procedure took place under general anaesthesia.
Given that most candidates for LAA occlusion are elderly, with
multiple co-morbidities, general anesthesia confers additional risk and
cost to the procedure. We examined the safety and cost implications
of performing this procedure under conscious sedation.
Methods: Fifty-four (44 men, 10 women; mean age
75.7 ± 6.2 years) with nonvalvular AF, at high risk for cardioembolic
stroke (mean CHA2DS2VASc score 3.8 ± 1.5), and high risk for oral
anticoagulation, underwent percutaneous LAA closure using the
WATCHMAN device. All procedures were performed under con-
scious sedation, with fluoroscopy and transoesophageal
echocardiography (TOE) guidance. The follow-up included clinical
and echocardiographic review within 45 days.
Results: The LAA was successfully occluded 50 patients (92.5 %) under
conscious sedation (fentanyl and midazolam). ASA PS score II-III. In four
cases, the device was not implanted due to unsuitable appendage anat-
omy. The mean procedural and fluoroscopy times were 61.3 ± 16.1 and
10.5 ± 5.4 min, respectively. The mean device size was 24.6 ± 3.8 mm.
There were no procedure, device or conscious sedation related compli-
cations. There were no statistically significant variations in monitored
blood pressure, heart rate or oxygen saturations during the procedure. All
procedures were performed as day-case procedures. Follow-up TOE
showed closure of all LAA orifices. No patient experienced any major
adverse event during a follow-up (5–22 months).
Cost saving implications were €3,174/patient, based on reduced
hospital stay, from standard 2 days of hospitalization (€1046/day) and
general anaesthesia saving (€1082/procedure).
Conclusion: Our study demonstrates that conscious sedation is a safe,
well tolerated alternative to general anaesthesia for percutaneous
LAA occlusion. Additionally, this approach facilitates LAA closure
as a day-case procedure, with a consequent reduction in procedure-
related costs and a significant saving in bed days.
51 Incidence and Outcome of Re-entry Injury in Redo
Cardiac Surgery
Imran Hamid U, Leung SCS, Soo LM, Graham A
Royal Victoria Hospital Belfast, Belfast
Introduction: Redo cardiac surgery may be associated with lethal
injuries to mediastinal structures. The purpose of this study was to
determine the frequency of injury during re-entry and identification of
pre-operative risk factors.
Methods: Review of a prospectively maintained cardiac surgery
database was performed. Five hundred and forty-four patients were
identified that underwent redo cardiac surgery between 2001 and
2011. Demographic details, re-entry injury, Euroscore, in hospital
mortality and nature of surgery were analysed.
Results: The mean age was 62 years; 326 were male, 218 were
female. 464 patients underwent first time redo while 80 patients had
multiple previous surgeries. 162 patients had pre-operative computed
tomography (CT) to identify proximity of vital structures to the
sternum; right ventricle in 25 % of patients, innominate vein in 7 %
and grafts in 5 % of cases. 35 patients had peripheral arterial (33
femoral and 2 axillary) cannulation to establish cardiopulmonary
bypass (CPB). 15 Intraoperative adverse events occurred. These
included injuries to aorta (n = 2), right atrium (n = 1) innominate
vein (n = 2), internal mammary artery (n = 2), pulmonary artery
(n = 2), lung parenchymal injury (n = 1), graft injury (n = 2), Injury
to right ventricle (n = 2), ventricular fibrillation (n = 1). Mortality in
this group was 26 % (n = 4) compared to 9 % (n = 48) without re-
entry complications. There were no mediastinal injuries reported in
the 6 % of cases where CPB was established prior to sternotomy.
Mean logistic Euroscore was 20.4. In hospital mortality was 9.5 %.
Conclusions: Risk of re-entry injury during repeat sternotomy is low,
however, re-entry injury significantly increases mortality. Pre-opera-
tive planning using CT scan is important in identifying structures at
risk during re-operations. Careful dissection and establishing CPB
prior to sternotomy minimizes such injuries in selected patients.
52 Radial Approach to CTO Re-canalisation is
as Successful and Safer than Femoral: Single Centre
Observational Study
Asgedom SD, Bjornsstad PM, Patten R, McAdam B, Sheahan R,
Foley DP
Beaumont Hospital, Beaumont, Dublin
Objectives: Despite increasing application of the radial route for PCI,
recanalization of chronic total occlusion has remained largely a trans-
femoral procedure, to allow use of larger catheters and achieve
powerful support. We adopted the radial approach as routine for all
PCIs including CTOs in 2007 and observed satisfactory treatment of
CTOs. In this study, we sought to compare procedural outcomes of
radial versus femoral approach to CTO in a consecutive patient series.
Methods and results: One hundred and forty-five (86 radial and 59
femoral) consecutive patients undergoing recanalization or attempted
recanalization of chronic total occlusion were reviewed. Mean age is
65.5 years and males constitute 84.4 %. There were no significant
differences in baseline clinical characteristics or in target vessel
between the two groups. All occlusions were[6 months old and up to
20 years. Bilateral radial access was used in 19.3 %; unilateral radial
in 78 % and 2 cases had radial ? femoral 5F diagnostic for contra
lateral injection. RCA was the target artery in 53.0 and 97.2 % had
multi-vessel disease. Overall success rate was 71.7 % and trans-radial
versus trans-femoral was 82.0 vs. 55.9 % (P value 0.001). The mean
fluoroscopy time was 24.9 min and was similar for both groups. No
significant difference in contrast use and flouroscope time was
observed. Access site complications were higher among trans-femoral
group than trans-radial. One case of pseudo-aneurysm and two major
bleedings were encountered in the femoral group whereas systemic
and coronary complications are similar for both groups.
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Conclusion: Radial approach for CTO re-canalisation did not hamper
success and actually was associated with higher success rates than
double femoral approach, probably thanks to improved guide-wire
and support micro-catheter technology during the 5 years covered.
Lower complication rates, with similar radiation exposure and con-
trast use encourage us to persist with the bilateral radial approach to
CTO as the default strategy.
53 An Audit of Acute Kidney Injury (AKI) Following
Contrast Coronary Angiography
Connolly M, Mc Eneaney D, Harbinson M, Morgan N
Cardiovascular Research, Craigavon Cardiac Centre, Southern Trust,
Northern Ireland
Background: 3,720 coronary angiograms were performed in Northern
Ireland in 2010. Coronary angiography and primary coronary inter-
vention (PCI) use iodinated contrast media but such agents can induce
renal tubular damage in susceptible individuals (contrast induced
nephrotoxicity, CIN). The strongest risk factor for CIN is the presence
of pre-existent chronic kidney disease (CKD), the UK incidence of
which is 5–8 %. Other risk factors include increasing age, diabetes,
hypertension and peripheral vascular disease [1]. Acute kidney injury
(AKI), defined as a serum creatinine rise[25 % from baseline, begins
within 24 h of contrast administration but is under-recognised at this
early stage using creatinine based methods. CIN is associated with
increased morbidity, mortality and duration of hospital stay. The
increasing burden of atherosclerotic diseases and consequent require-
ment for angiography/PCI positions CIN as a major healthcare issue.
Aims: The aims of this study were to record the number of patients
having coronary angiography who have CKD, and document the
proportion who developed AKI.
Methods: Patients undergoing coronary angiogram at Craigavon
hospital between 01/08/2010 and 01/02/2011 were selected. Renal
function was recorded prior to angiogram. Patients identified with
significant CKD (estimated glomerular filtration rate \60 mls/min)
had follow up renal function testing 48 h post contrast to assess for
AKI development.
Results: 634 angiograms were performed. 77 patients (12.1 %) had
an eGFR\60 mls/min. Nine patients (11.6 %) developed AKI. Mean
age was 77.1 years (range 69–85 years). Affected patients demo-
graphics and risk factors were recorded (Table 1).
Table 1 Patient summary and associated AKI risk factors
No of patients eGFR \60 (%)
Developed AKI 9 (11.6)
CRF Stage 3 8 (88.8)
CRF Stage 4 1 (11.1)
Hypertension 6 (66.6)
Diabetes 1 (11.1)
Mean contrast dose (range) 132mls (100-190mls)
ACE-I/ARB 7 (77.7)
Diuretic 4 (44.4)
MACE at 6 months 2 Deceased (22.2)
Conclusion: CIN is common post angiography. It exceeds 10 % in
CKD patients and is set to rise. Unfortunately serum creatinine is a
delayed marker of GFR decline [2], novel biomarkers to detect early
CIN are urgently required. This could facilitate early intervention to
protect renal function, reduce morbidity, improve prognosis and reduce
length of hospital stay. Such markers will be the focus of further study.
References
1. Lautin EM, Freeman NJ, Schoenfeld AH et al (1991) Radiocon-
trast-associated renal dysfunction: incidence and risk factors.
AJR Am J Roentgenol 157(1):49.
2. Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal
insufficiency. Am J Kidney Dis 39:930–6.
54 Long-Term Survival of Patients Successfully
Discharged Following Aborted Out of Hospital
Cardiac Arrest
J Keaney, S Cuddy, L Browne, A Hanley, J O’Sullivan,
N Mahon, E Keelan, C McGorrian, J Galvin
Mater Hospital Dublin
Background: While there is an extensive awareness of factors which
improve survival to discharge for patients with out-of-hospital cardiac
arrest (OOHCA), there remains a lack of data internationally on the
long-term outcomes of these patients.
Methods: This is a retrospective observational study in which outcomes
of patients discharged from the Mater Hospital following OOHCA from
July 2003 to August 2011 were determined by means of hospital record
review, or contacting the patients primary care physician.
Results: During the period under review 1,217 patients presented to
the emergency department of our hospital following OOHCA. Only
76 (6.2 %) patients survived to discharge. The mean age of survivors
was 53.7 ± 15 years. 93.7 % of OOHCA survivors had been de-
fibrillated on-site and bystander cardiopulmonary resuscitation was
carried out in 77.8 %. Acute ST-elevation myocardial infarction
(STEMI) was the underlying cause of the arrest in 45 % of cases.
Implantable cardioverter-defibrillators (ICDs) were inserted in 47.4 %
prior to patient discharge.
Mean time since cardiac arrest was 45.3 ± 27.3 months. No patients
were lost to follow-up. 85.5 % (65/76) of patients were still alive on
review. 11.8 % (9/76) were diagnosed as having hypoxic brain injury.
There were non-significant trends towards improved survival in
patients presenting with STEMI (88.5 vs. 82.9 %). A similar finding
was observed in patients with ICDs inserted prior to discharge (88.9
vs. 82.9 %). There was no difference in survival rates between
patients aged 65 or older (n = 18), compared with younger survivors
(83.3 vs. 85.4 % survival).
Conclusion: Once patients survive to hospital discharge, long-term
survival following aborted OOHCA is excellent.
55 Utility of Highly-Sensitive Cardiac Troponin I
as a Marker of Disease in Hypertrophic
Cardiomyopathy
1,2McGorrian C, 3Lyster S, 4Tarrant H, 2Codd M, 5Doran P,
4Fitzgibbon M, 1,6Galvin J, 1Mahon NG
1Department of Cardiology, Mater Misericordiae University Hospital;
2UCD School of Public Health, Physiotherapy and Population Science,
UCD; 3UCD School of Biomolecular and Biomedical Sciences, UCD;
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4Department of Clinical Biochemistry, Mater Misericordiae Univer-
sity Hospital; 5UCD Clinical Research Centre , Mater Misericordiae
University Hospital; 6Department of Cardiology, Connolly Hospital
Blanchardstown
Introduction: Hypertrophic cardiomyopathy (HCM) is a genetic
condition characterised by cardiac muscle hypertrophy with myocyte
disarray. HCM may have a clinically silent latent period during which
there can be a risk of arrhythmic events. Cardiac troponin may be
elevated in HCM. We examined the predictive ability of cardiac
troponin I estimated by contemporary and newer highly-sensitive
assays for HCM.
Methods: Nested case–control study of consecutive HCM patients and
relatives who attended for HCM screening, from May 2010 to Sep-
tember 2011. Cases had possible or definite HCM as defined by standard
Maron criteria. After informed consent, participants provided venous
blood samples, and clinical features were recorded. Analyses were
performed using the contemporary ARCHITECT STAT Troponin-I
assay (cTnI) and high sensitive Troponin-I (hsTnI) assay on the
ARCHITECT i1000SR (Abbott
TM). Associations between the natural log
(ln) of cTnI and hsTnI and markers of cardiac hypertrophy were
examined using Pearson’s correlation coefficient and logistic regression.
Results: Complete clinical data were available on 107 patients, of
whom 24 had borderline and 19 had overt HCM. Both ln(cTnI) and
ln(hsTnI) were seen to have significant, positive correlations with
maximal wall thickness (r = 0.42, p \ 0.001, and r = 0.51,
p \ 0.001, respectively) and left ventricular mass (r = 0.66,
p \ 0.001, and r = 0.52, p \ 0.001, respectively). After age and sex
adjustment, the area under the receiver operator characteristic (ROC)
curve for HCM was 0.78, 95 % CI (0.65, 0.90) for ln(hsTnI), and 0.66,
95 % CI (0.51, 0.82) for ln(cTnI). This difference was not statistically
significant (p = 0.11).
Conclusions: This is the first description of a hsTnI assay in a HCM
population. Both cTnI and hsTnI were shown to have a graded,
positive association with measures of cardiac hypertrophy in persons
with and at risk of HCM. Highly-sensitive TnI may have better dis-
crimination for HCM than the contemporary assay, although further
studies will be required to investigate this.
56 Implications of Following New NICE Guidance
on pts Presenting to the Rapid Assess Chest Pain Clinic
Shevlin S, Johnston N, Dougon J
Royal Victoria Hospital, Belfast
Introduction: 8,400 patients attend a Rapid Assess Chest Pain Clinic
(RACPC) in Northern Ireland yearly. The majority undergo exercise
stress testing (EST) as the first-line diagnostic investigation. New
guidelines released by NICE in 2010 for investigation of patients with
stable anginal symptoms do not include EST in the investigation
algorithm. Instead the 1st line diagnostic test is based on a risk cal-
culation of likelihood of coronary artery disease (CAD). The
diagnostic tests utilised are CT calcium scoring, functional imaging or
invasive diagnostic angiography. The aim of this prospective obser-
vational study was to assess the potential impact within Belfast of
implementing the updated NICE guidelines
Methods: All patients without a previous history of CAD attending
the RVH RACPC between the 1st October and 31st November 2011
where included. CAD risk was calculated using tables published by
NICE using their age, sex, typicality of angina pain and risk factors
present. Initial investigations performed at the RACPC were recorded
as well as the recommended Investigations as per NICE guidelines.
Results: 173 patients attended (50 % male) and mean age was 55
(range 30–82). Of these, 94 % underwent EST, 5 % SPECT imaging
and 1 % were discharged with no investigation. Using the current
algorithm no patient underwent invasive angiography or CT imaging
as first line testing. Using the NICE guidelines 26 % of patients would
require no diagnostic test, 21 % would require CT imaging, 27 %
functional imaging and 26 % invasive angiography. Only 3 of 173
participants (1.7 %) were NICE compliant.
Conclusion: Whilst results suggest that implementation of NICE
guidelines would result in the discharge of significantly more patients
who require no investigation, this will be offset by a significant
increase in demand for cardiac CT, functional stress testing such as
SPECT or stress echocardiography and particularly invasive coronary
angiography. This will have significant cost and training implications
as availability of the imaging tests recommended by NICE needs to
dramatically improve.
57 Pericardial Effusion Associated with Neoadjuvant
Chemoradiation for Oesophageal Cancer at a Tertiary
Referral Centre—An 8-year Experience
Sugrue R, Fitzgerald C, Molony P, O’Hare D, McCormack O,
Ravi N, Murphy R, Daly C, Reynolds JV
Departments of Upper Gastrointestinal Surgery and Cardiology,
St James University Hospital, Trinity College, Dublin
Aim: Pericardial effusion may be associated with radiotherapy for
oesophageal cancer [1, 2]. This association is rarely reported, how-
ever, for patients receiving preoperative (neoadjuvant) therapy. This
study examined the incidence and correlates of pericardial effusion in
patients receiving standardised neo-adjuvant chemo-radiotherapy
(nCRT) protocol at a tertiary oesophageal centre over 8 years.
Methods: Patients commencing nCRT between June 2003 and June
2011 were identified from an institutional oesophageal cancer regis-
try. Clinical and demographic variables were collected, as were data
on chemotherapeutic regimen, radiotherapeutic fraction size and
dosages, and postoperative pathology. All pre-therapeutic and sub-
sequent echocardiographic and computed tomography examinations
were reviewed. Data were analysed using SPSS, using the 2-sample
t test and Chi-square test as appropriate.
Results: Pericardial effusion occurred in 33 of 220 patients (15 %)
receiving nCRT. All patients received either cisplatin-5 flourauracil
(C5FU) or etoposide-oxaloplatin (EOX) protocols and standardised
radiotherapy with a mean dosage of 40.3 Gray. None had an effusion or
pericardial thickening prior to radiotherapy. Median interval from ini-
tiation of therapy to effusion was 8.5 months (range 2.9–35.6 months).
Effusion occurred in 27.8 % of all patients with mid-oesophageal
malignancy, compared with 12.4 % for lower oesophageal or junc-
tional tumours (p = 0.02). Females appeared more likely than males to
be affected [21.4 vs. 12.7 %; (p = 0.09)]. Pericardiocentesis was per-
formed in 7 patients; 2 patients required pericardiectomy.
Conclusion: Pericardial effusion occurred in 15 % of patients
receiving nCRT. This was significantly associated with mid-oesoph-
ageal tumours (p \ 0.05), and approached significance in females.
Although medical (3.2 %) and surgical (0.9 %) interventions are rare,
the study suggests that prospective studies of cardiac/pericardial
consequences of nCRT should be encouraged.
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58 A Comparative Cost Impact Study of Diamond
Forrester and Coronary Calcium
McKavanagh P, Lusk L, Ball P, Trinick T, Duly E, Walls G,
Harbinson M, McQuillan CL, Shevlin S, Alkali M, Donnelly P
Department of Cardiology, Ulster Hospital, Dundonald, Belfast
Objective: To determine the accuracy and cost impact of the diamond
forrester (DF) and calcium score (CS) pathways proposed by NICE
clinical guideline 95 (CG95).
Method: This was a sub-study of the Cardiac CT for the Assessment
of Chest Pain and Plaque (CAPP) study, a larger randomised control
trial (ISRCTN52480460), evaluating the cost-effectiveness of cardiac
CT in stable patients. The CAPP study recruited 500 participants
referred to NHS Rapid Access Chest Pain Clinics with suspected
coronary artery disease. This work involved the 250 patients ran-
domised to the CT arm of the CAPP study. The total number and cost
for initial and further investigations was determined theoretically by
two models. Model A used the DF criteria and Model B the CS
criteria.
Results: Of the 250 patients, 4 withdrew. 140 (57 %) patients were
male. The mean DF was 47.8 and mean CS 172.5. Of the 52 patients
that had a DF score of 0–9 % 1 (1.9 %) had severe disease and of the
91 that had a DF[60 % 17 (18.7 %) had no CAD. Of the 126 patients
that had a CS of zero 2 (1.6 %) patients had severe disease and of the
26 patients with a CS [400 only 4 (15.4 %) did not have severe
disease. A Kendall’s Tau-c (sc), rank correlation coefficient was
performed with CS showing a better correlation (sc = 0.768,
SE = 0.026) withCAD compared to the DF (sc = 0.44, SE = 0.047).
In the costing analysis CS proved to be less expensive in all scenarios
considered.
Conclusions: The use of CS to triage all patients appears to be more
economical and accurate for the prediction of CAD and prevents
unnecessary downstream testing.
59 Routine Trans-oesophageal Echocardiography
Directed Cardioversion in Patients with Atrial
Fibrillation Treated with Dabigatran–a Single Centre
Experience
Kennedy MW, Waterhouse DF, Sheahan R, Gumbrielle T,
Foley DF, McAdam BF
Dept of Cardiology, Beaumont Hospital, Dublin
Introduction: Increased risk of cardio-embolic events following
direct current cardioversion (DCCV) is well recognised. According to
guidelines and observational studies, Warfarin is required for at least
3 weeks before, and a minimum of 4 weeks after cardioversion
because of the risk of thrombo-embolism. Indeed transopesophageal
echocardiogram (TOE) to exclude thrombus does not preclude
embolism afterwards. With new anti-coagulants such as Dabigatran,
limited clinical trial experience suggests that this strategy is possible
and safe but the monitoring of anti-coagulant status is not possible.
Our institution adopted a pre DCCV TOE policy for all patients on
this agent. We present the findings of our cohort of patients on Da-
bigatran who underwent a day case TOE guided DCCV and its effect
on coagulation indices.
Methods: In total 43 patients were pre treated with a minimum of
4 weeks of Dabigatran at the appropriate dose underwent day case
TOE guided DCCV. All patients underwent a thorough evaluation of
their left atrium and appendage and assessment of LAA velocities by
Pulse Wave (PW) Doppler. TOE negative patients underwent DCCV
on that day.
Results: Of the 43 patients (mean age 67.38 ± 9.76, males 33;
females 10) no patient was found to have a LAA thrombus and all
were able to proceed to DCCV. The mean LAA exit velocities in
this group were 41.66 ± 16.06 cm/s, mean PT 18.95 ± 3.36, mean
APTT 55.22 ± 8.54 and mean INR 1.61 ± 0.37. No patient expe-
rienced any adverse clinical neurological events after routine
6 weeks of follow up.
Conclusion: Despite the inability to monitor Dabigatran, providing
compliance to medication prior to DCCV, no patient was found to
have a LAA thrombus or adverse neurological event in follow up.
Anticoagulation indices may indicate drug effect but are unreliable
markers of therapeutic effectiveness.
60 A Pilot Study on Renal Sympathetic Denervation
for Resistant Hypertension in the West of Ireland
Kalyar I, Gleeson J, Lappin D, Crowley J, Nash P,
MacNeill B, Daly K, Sharif F
Cardiology Department, Galway University Hospitals, Galway
Objective: Renal Sympathetic Denervation (RSD) is a novel, device-
based intervention for the management of resistant essential hyper-
tension (RH). Here we present the data from our initial experience of
renal artery denervation for the first 12 patients.
Methods: All patients in this pilot study (n = 12) had RH, and were
on a minimum of 3 medications. The effect of RSD on office blood
pressure, 24 h ambulatory blood pressure, number of anti-hyperten-
sive medications, renal function, weight, serum uric acid
concentration, excretory fraction of sodium, and renin-aldosterone
levels was investigated. We also assessed the safety of the procedure.
Prior to intervention secondary causes of hypertension were excluded,
and detailed anatomy of the renal arteries was obtained using either
CT or MR angiography. Patients were followed up at 2 weeks,
2 months and 6 months for serum biochemistry, urinalysis and office
BP. Ambulatory BP was assessed pre- and 2 months post RSD.
Results: At 2 months the average decrease in office BP was
33/15 mmHg (systolic p = 0.04, diastolic p = 0.03), while the
observed reduction in 24 h ambulatory BP readings was 26/16 mmHg
(systolic p = 0.01, diastolic p = 0.01). The range in change of serum
creatinine values at 2 months was -10 to ?13 lmol/L, and the average
change was ?1.5 lmol/L (p = 0.47). There was a 6.6 % reduction in
mean uric acid concentration (p = 0.371). A trend towards weight loss,
with an average reduction in weight of 1.65 kg at 2 month follow up
was seen (p = 0.27). Patients required, on average, 1.3 medications less
at follow up. There have been no major complications to date.
Conclusion: RSD was safe, and effective at reducing both systolic
and diastolic blood pressure in patients with RH. No acute
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deterioration in renal function was demonstrated. Findings from this
pilot study showed more substantial reductions in ambulatory BP
consistent with larger studies.
61 ABC for Life: a Programme of BLS Training
to Primary School Children in Northern Ireland
Since 2004
Mc Grath P, Laverty L, Toner P, Connolly M
‘ABC for life’ charity committee, Queen’s University Belfast,
Northern Ireland
The ABC for Life programme is a regional course in basic life support
(BLS) training in Northern Ireland specifically designed for 10–12 year
old children. It was set up in 2004 by a team of dedicated medical students
and the Division of Medicine at Queens University Belfast (QUB).
Medical students are trained as instructors of BLS and subse-
quently attend primary schools and education training boards to
instruct teachers how to train their pupils. A bank of trained medical
student instructors is in constant use, supervised by two student
coordinators. The scheme is overlooked by the ABC for life com-
mittee including postgraduate doctors and representatives from the
Division of Medicine at QUB.
Resource packs (DVDs of a cardiac arrest situation, a simple faint
requiring recovery position, communication with ambulance control,
an instruction manual and a training manikin) are provided to each
school to retain for future training sessions. Refresher courses are
offered yearly. A dedicated website via QUB is in use for teachers to
access resources and contact the coordinators if needed.
We have previously shown that children trained through his
unique training programme showed a highly significant increase in
knowledge following the training session, which remained higher
than non-trained pupils at 6 months following training [1, 2]. An
official charity status has been granted and the charity committee
continue to raise funds to purchase equipment.
By using medical students and teachers, a large number of children
can be trained. To date, the programme has trained and provided
resources to approximately 300 schools in Northern Ireland. With an
average primary school class containing 25 pupils, we estimate that
7,500 pupils have been trained. We plan to continue training, provide
refresher courses and expand our training to include use of an auto-
mated external defibrillator (AED).
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62 Initial Experience with Vernakalant for Rapid
Conversion of New Onset Atrial Fibrillation
Abidin NZ, Waterhouse DF, Foley D, Sheahan RS, McAdam B
Department of Cardiology, Beaumont Hospital, Dublin
Introduction: Intravenous vernakalant is an atrial-repolarization-
delaying agent, approved for the rapid conversion of recent-onset
atrial fibrillation (AF) to sinus rhythm (SR). Vernakalant blocks
atrial-specific potassium and sodium ion channels, slowing atrial
conduction, without promoting ventricular arrhythmia. The aim of
this study was to assess the safety and effectiveness of vernakalant for
the acute conversion of recent-onset AF.
Methods: Patients with new onset AF \48 h, eligible for cardio-
version, were enrolled over a 6 month period. The inclusion criteria
included preserved left ventricular function, no concurrent acute
coronary syndrome or use of class III anti-arrhythmic drugs and no
obvious precipitant of AF. All the patients enrolled in this study
received a 10-min intravenous infusion of vernakalant (3 mg/kg). If,
after a 15-min observation period, AF was still present, a second
10-min infusion of intravenous vernakalant (2 mg/kg) was given. The
primary end point was conversion to SR within 90 min.
Results: Twenty (male n = 14, female n = 6) haemodynamically
stable patients with AF received intravenous vernakalant. Mean age
of the population was 63 years. The primary end-point of conversion
to SR within 90 min was achieved in 95 % of patients (n = 19), with
a median time to conversion of 62 min. Transient side effects inclu-
ded nausea (35 %, n = 7) and sneezing (20 % n = 4). Mild
hypotension was seen in 55 % (n = 11) with a mean fall in systolic
BP of 16 mmHg. There were no significant side effects requiring
discontinuation of the infusion. No ventricular arrhythmias were
associated with this treatment strategy in the studied population.
Conclusion: Vernakalant rapidly converted recent-onset AF to SR,
was well tolerated, and may be a valuable therapeutic strategy for
reestablishing SR in patients with recent-onset AF.
63 Current Use of Oral Anticoagulation in Atrial
Fibrillation Patients
Morgan RB, Mahon C, Sugrue R, Lynch M, Blennerhassett L,
Curtin E, McMahon G, Murphy RT, Mulvihill N, Foley B,
Crean P, Daly CA
St James’s Hospital, Dublin
Background: Atrial fibrillation (AF) is associated with significant
morbidity and mortality, particularly stroke. Consequently a critical
component of the management of atrial fibrillation is the prevention or
embolic complications through anticoagulation. The advent of multi-
ple novel anticoagulants in recent years has led us to question the
actual use of existing oral anti-coagulation (OAC) agents in practice.
Methods: Prospective observational study in a Dublin university
teaching hospital. Consecutive patients over 2 months with AF
detected on admission ECG or on telemetry during hospital stay were
included and patient demographics, clinical details, inpatient treat-
ments and discharge medications are presented. CHADS and
CHADSVASC scores were calculated for all patients and patient were
categorised into two groups, OAC indicated or OAC not indicated
based on CHADSVASC score C2 or \2.
Results: During the study period 169 patients who presented to ED or
were admitted to hospital had AF. Mean age 75 (±11); 49 % male.
Clinical type of AF 18 % new, 17 % paroxysmal, 8 % persistent,
52 % longstanding persistent and 5 % unknown. At presentation
76/169 (45 %) of patients were on oral anticoagulation. The mean
CHADS score in our population was 2.41 and CHADSVASC was 4.
OAC status at discharge is shown on Table 1. INR measurements in
the ED revealed 17/77 (22 %) of patients on warfarin were subther-
apeutic at presentation; 46/77 (60 %) were within target range; 7
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(9 %) had an elevated INR and 7 (9 %) had no INR recorded. No
patients received noncoumarin-based novel oral anticoagulant agents.
Table 1 OAC prescribing patterns
Warfarin prescribing % age of
patients
Not indicated, not prescribed 11
Not indicated, prescribed 0
Indicated, not prescribed, no reason documented 14
Indicated and prescribed 52
Previous major bleed on OAC 2
Indicated but decision made by team against
OAC based on perceived unsuitability
16
Patient died 5
Conclusion: No patients were inappropriately anti-coagulated and
none received novel non-coumarin based OAC. However, despite
high CHADSVASC scores in our population only 52 % of patients
were on OAC at discharge. Why this proportion is so low, and why
the proportion of patients perceived to be unsuitable for anticoagu-
lation is so high deserve further study and may have important
implications for routine use of novel anticoagulation agents in AF.
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